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Following the 2013–2016 West Africa Ebolavirus (EBOV) outbreak, a broad 
range of scientific research has been conducted to understand and prevent 
future epidemics. Our current study, supported by the United States Food and 
Drug Administration (FDA), uses sero-epidemiology to look at the footprint in-
cidence of EBOV and Lassa virus (LASV) in the prefecture of Macenta located 
in forested Guinea. Our study assesses seroprevalence of these zoonotic vi-
ruses in bushmeat hunters and their household members. These groups of 
people are at risk of exposure to multiple viral zoonotic infections via constant 
contact with wildlife, either by hunting, trapping or butchering. In order to in-
vestigate potential historical EBOV and/or Lassa virus LASV infections, serum 
samples were collected from villages that were affected or unaffected by the 
2013-2016 EBOV outbreak in Guinea. We performed Enzyme-Linked Im-
munosorbent Assay (ELISA), western blot analysis and flow cytometry for the 
detection of EBOV glycoprotein (GP) and LASV nucleoprotein (NP) antigens 
specific immunoglobulin G. A number of positive samples were detected for 
both pathogens, suggesting that these two pathogens are circulating in Guinea 
and may cause mild or asymptomatic infection in a proportion of cases. Im-
portantly, this study suggests EBOV may have been circulating in Guinea be-













Hypothesis of the Thesis 
The primary purpose of this study is to assess to what extent Ebolavirus has been 
circulating within the forested region of Guinea prior to the 2013-2016 Ebola virus 
disease (EVD) outbreak in West Africa. Due to the nature of their work, bushmeat 
hunters and their household family members are deemed to be at high risk of Ebo-
lavirus contamination and spill over. We then established a cohort of bushmeat hunt-
ers and their immediate families and collected serum samples from volunteers. We 
looked for the presence of anti-Ebolavirus antibodies to determine previous exposure 
to the virus. Our cohort includes bushmeat hunters from villages affected by the 2013-
16 Ebolavirus outbreak and villages that were not affected. Therefore, we hypothe-
sized that a number of samples from previously non exposed villages to EVD will 
contain anti-Ebolavirus antibodies, suggesting that the virus has been circulating or 
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1.1  Ebola virus 
 
Over the last 50 years, there has been a large increase in the occurrence of new 
diseases that affect humans. Many of these emerging infectious diseases are zoon-
otic in nature, in that they are transmitted from animal to human. Increased contact 
between humans and wildlife through activities such as agriculture and hunting pro-
vide an opportunity for these pathogens to spill-over and cause disease in the human 
population. Ebolavirus (EBOV) are one such zoonotic pathogen, causing high rates 
of mortality and social unrest.  
 
1.1.1 Discovery of Ebola virus 
EBOV was first discovered in 1976 in Central Africa near the river Ebola in Bomba 
zone at Yambuku village1, the virus was named after the Ebola river which means 
“Clear” in the local language. Initially, this previously unknown haemorrhagic fever 
outbreak was thought to have started in South-Sudan and then later expanded to the 
Northern region of the Democratic Republic of Congo (DRC), formally Zaire1. It is 
reported that a 42-year old patient was admitted to Yambuku Mission Hospital (YMH) 
with an unknown haemorrhagic fever and was treated for malaria1. Later, several pa-
tients from the zone treated in YMH with non-sterilized materials, such as syringes, 
presented with similar symptoms. A team from Kinshasa and the Belgian institute for 
tropical medicine was sent to Yambuku to collect samples which were then sent to 
laboratories with high containment facilities. Those Microbiological Research Estab-
lishments (MRE) included that of Porton Down in England and the Center for Disease 
Prevention and control (CDC) at Atlanta, Georgia for analysis1. The unknown virus 
was grown in animals (New borne mice, weaning mice and Guinea pig) and into cell 
lines (Vero cells and patient liver). Marburg-like virus particles were identified by neg-
ative contrast electron microscopy (EM)1. Moreover, serological testing was per-
formed by Patricia Webb (CDC) using Yambuku convalescent serum for this new 
circulating virus1. Reports indicate that there were 318 cases with 280 deaths during 
the Yambuku outbreak, giving a case fatality rate of almost 90 %, this species of 





1.1.2 Notable historical outbreaks 
There have been 27 notable Ebola virus disease (EVD) outbreaks to date which have, 
in the most part, been restricted to countries around the Congo basin: Gabon, South-
Sudan, Uganda, Angola, DRC, and Congo-Brazzaville (Table 1). Notable Outbreaks 
of EVD, leading to newly identified species, have occurred in Sudan (Sudan ebo-
lavirus), Uganda (Bundibugyo ebolavirus) and Ivory Coast (Tai Forest ebolavirus).  
The first haemorrhagic fever outbreak in Sudan occurred during 1976 in Nzara and 
Maridi (Southern Sudan)3. The disease was first identified among farmers working in 
the cotton industry of Nzara. It was described as a severe illness with bleeding com-
plications and simultaneously spread between Nzara and Maridi located about 250 
km away4. The World Health Organization (WHO) was alerted and specimens were 
collected from infected patients for viral isolations and identification via histopathology 
and electron microscopy analysis at CDC (Atlanta), the MRE of Porton Down (Eng-
land) and in Bernhard Nocht Institute for Tropical Medicine (Germany)4. The isolated 
virus was named Sudan Ebolavirus (SUDV) and the case fatality rate was recorded 
as approximately about 53 %5. 
Furthermore, in 1994 another new ebolavirus species was identified in the Ivory Coast 
within the national Tai Forest park, the virus was detected amongst chimpanzees and 
troops near the Liberian border5. In the Tai Forest park, several cases of chimpanzee 
death were reported during the same period. To investigate these chimpanzee 
deaths, three scientific ethologists conducted a necropsy on one chimpanzee corpse 
found in the forest, this chimpanzee was subsequently tested positive for EBOV via 
indirect fluorescent antibody (IFA) test and enzyme linked immunosorbent assay 
(ELISA) at the Pasteur Institute in France. The newly discovered haemorrhagic fever 
virus was named the Tai Forest virus (TAFV). Later, a Swiss ethologist actively work-
ing on infected chimpanzees in the Tai Forest park was infected when performing a 
necropsy on another dead chimpanzee corpse. She was rigorously treated with fluid 
and electrolyte replacement therapy and fully recovered 6 weeks later with no sec-
ondary transmission to humans5.  
During April 1995, a laboratory staff member of Kikwit hospital in the DRC was admit-
ted to the viral haemorrhagic fever (VHF) unit6. As he underwent treatment, the entire 
caring medical staff presented with similar symptoms. Blood samples from acute pa-
tients were collected and analysed by ELISA for EBOV antigen or antibody at CDC in 
a high containment biosafety environment6. Additionally, reverse transcription poly-
merase chain reaction (RT-PCR) test was performed to detect viral RNA and addi-
tional investigations revealed that the new Zaire ebolavirus was closely related to that 
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of EBOV, identified in 19766. The newly discovered virus was reported to have in-
fected 317 people amongst which 245 succumbed to disease giving a case fatality 
rate of 79 %7. 
Reston ebolavirus is the first ebolavirus species reported outside Africa. Notably, 
Reston virus (RESTV) was identified between 1989 and 1996 during a haemorrhagic 
fever outbreak in Cynomolgus macaques exported from Philippines and China to a 
non-human primate facility in Reston, Virginia in the United States10. An ELISA test 
performed on 179 blood samples to assess the prevalence of RESTV amongst animal 
handlers indicated a seroconversion rate of 3.4%8. Furthermore, an animal handler 
who cut himself while performing a necropsy on an infected macaque liver failed to 
become sick8. Though the virus is known to cause severe haemorrhagic fever in non-
human primates, experiments indicate that RESTV does not cause any illness in pigs 
and human9. It was then concluded that RESTV is asymptomatic in humans.   
In 2007, haemorrhagic fever was notified in Bundibugyo district in Western Uganda10. 
Samples were collected from 29 patients and tested negative for known filoviruses 
(EBOV and Marburg viruses). In addition, a newly developed metagenomic pyro-se-
quencing method was performed using traditional primer approaches10. Acquisition 
of these sequences revealed that it was in fact an EBOV that was circulating in Bun-
dibugyo district. The identified virus was different to the four EBOV species previously 
discovered10. The newly discovered virus was then named after the place of its dis-
covery: Bundibugyo virus (BDBV)10. Reports finally indicate that the Bundibugyo out-
break resulted in 149 suspected cases with 37 deaths giving 25% case fatality rate10.  
In 2002, a new ebolavirus specie (LIoviu Cuevavirus) with one single virus type, LIoviu 
virus (LLOV) was discovered in Cueva del LIoviu (Asturias) in Spain11. The virus was 
identified from Schreiber long-fingered bats (M. schreibersii).  A mysterious discovery 
of several corpses of M. Schreiber bats and giant mouse (M. myotis) found in a cave 
and suggested to have succumbed to an unknown disease lead to serious scientific 
search which resulted in LLOV discovery only in bats. Additionally, a new ebolavirus, 
Bombali virus (BOMV) has recently been discovered in Sierra Leone in free-tailed 
bats (Chaerephon pumilus)12. Presently, no study has documented both LLOV and 
BOMV infection disease in human or NHPs. 
The West African Ebola virus disease (EVD) epidemic was known as the biggest, 
largest and deadliest ever since the discovery of the virus with 28,616 confirmed 
cases amongst which 11,310 deaths occurred13. The outbreak greatly impacted pub-
lic health systems in the three main affected countries (Guinea, Liberia and Sierra 
Leone)14. Currently, 2,236 people have succumbed to an on-going EBOV outbreak in 
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the DRC (North Kivu and Ituri provinces)15. With 3,409 confirmed cases since August 
2018, the outbreak is known as the second biggest epidemic of the virus on record. 
 
Table 1: Ebolavirus outbreaks in Africa since 1976 
Location of outbreak of the Ebolavirus and total laboratory confirmed cases. 
 Year Country Virus Cases Deaths 
1976 DRC Zaire ebolavirus 318 280 
1976 Sudan Sudan ebolavirus 284 151 
1977 DRC Zaire ebolavirus 1 1 
1979 Sudan Sudan ebolavirus 34 22 
1994 Gabon Zaire ebolavirus 52 31 
1994 C. d’ivoire Tai forest ebolavirus 1 0 
1995 DRC  Zaire ebolavirus 315 254 
1996 Gabon Zaire ebolavirus 31 21 
1996 Gabon Zaire ebolavirus 60 45 
1996 South Africa Zaire ebolavirus 1 1 
2000 Uganda Sudan ebolavirus 425 224 
2001 Gabon Zaire ebolavirus 65 53 
2001 DRC Zaire ebolavirus 59 44 
2003 DRC Zaire ebolavirus 143 128 
2003 DRC Zaire ebolavirus 35 29 
2004 Sudan Sudan ebolavirus 17 7 
2005 DRC Zaire ebolavirus 12 10 
2007 DRC Zaire ebolavirus 264 187 
2007 Uganda Bundibugyo ebolavirus 149 37 
2008 DRC Zaire ebolavirus 32 14 
2011 Uganda Sudan ebolavirus 1 1 
2012 Uganda Sudan ebolavirus 24 17 
2012 Uganda Sudan ebolavirus 7 4 
2012 DRC Bundibugyo ebolavirus 57 29 
2014 DRC Zaire ebolavirus 66 49 
2014-16 West Africa Zaire ebolavirus 28,616 11,310 
    
 
Finally, it is worth noting that there have been previous suspected EVD outbreaks in 
Guinea. Between 1982-1983, an unknown hemorrhagic fever disease was reported 
amongst populations in the Madina Ula, district of Kindia region (Republic of 
Guinea)188. A serological survey conducted amongst convalescent people in the af-
fected area (Madina Ula) revealed 19 % sero-positivity to EBOV. Although, the study 
revealed 8 % EBOV antibody detection amongst the healthy population and 3 cases 
of exposure to Lassa virus (LASV). The serological testing used ELISA assays prob-
ing all EBOV and LASV antigens. In addition, a recent study on probable existence 
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of EBOV in Guinea prior to the 2013-2016 outbreak has been published16. In this 
study, blood samples were broadly collected in Guinea in 2012 as part of a demo-
graphic and health survey program. The program was led by the national institute of 
statistics.  Those collected samples were tested on Luminex-based assay technology 
and revealed the presence of EBOV-specific antibodies in one specimen. The identi-
fied case was known to be from the forested region of Guinea (Nzerekore), but it was 
uncertain whether the individual had traveled from a known EBOV endemic area such 
as the DRC.  
 
Figure 1: WHO map of ebolavirus outbreaks in Africa since 1976.  
Four ebolavirus species have been simultaneously circulating in Africa. The most frequent is 
the Zaire ebolavirus followed by Sudan ebolavirus. Tai forest ebolavirus had occurred once in 
Ivory Coast (1994) whereas the Bundibugyo ebolavirus had appeared twice in Uganda (2007) 
and in the DRC (2012). 
 




1.1.3 Ebola; Species and phylogenetics 
Filoviruses are members of the Mononegavirales order and the Filoviridae family 
which is composed of three genera: Cuevavirus, Ebolavirus and Marburgvirus17 (Ta-
ble 2). The international committee on taxonomy of viruses (ICTV) has named Filo-
viridae after its morphological structure which is filamentous (Filum) and the virus 
family (viridae)18. It follows that Filoviruses are known to appear in multiple shapes 
which are either long or short filaments. Those Filaments (particles) are sometimes 
branched, circular or presented in a ‘’6’’ or ‘’U’’ form and extend from 650 to 14,000 
nanometres in length, 80 nanometres in diameter. Virions are enveloped in a lipid 
membrane and their surface covered with a single glycoprotein that is dispersed in 
spikes14. In addition, the filoviruses genome is approximately 18 to 19 kb long and 
encodes for seven proteins including nucleoprotein (NP), glycoprotein (GP), virion 
proteins (VP) 24 , VP30, VP35, VP40 and the large (L) protein19. Both ebolavirus and 
marburgvirus are morphologically filamentous particles and have a negative-sense 
single-stranded RNA (ssRNA) genome13,14. 
To date, no case fatalities in humans have been reported for Cuevavirus. The type 
virus of the Cuevavirus genus, LIoviu virus (LLOV) was initially discovered in Cueva 
del LIoviu (Asturias), Spain in 200211,20. The virus was identified from Schreiber long-
fingered bats (Miniopterus schreibersii). This finding was a result of a mysterious dis-
covery of several corpses of Schreiber’s bats and giant mice (Myotis myotis) in a cave 
and suggested to have succumbed to an unknown disease. The newly discovered 
virus was named LLOV after the Spanish region where it was discovered (Cueva 
mains cave). Unfortunately, LLOV viral RNA was only found in bats but not in the 
mice. Additionally, another study from a deceased bat in Spain not only identified 
LLOV but also revealed that LLOV expresses seven structural proteins (NP, VP35, 
VP40, GP, VP30, VP24, and L-protein) from six genes in contrast to other Filoviruses 
which encode seven genes17. 
Table 2: Filoviridae; Genus and Species 
 
Genus name Species name 
Cuevavirus LIoviu cuevavirus 
Ebolavirus Bombali Ebolavirus 
 Bundibugyo Ebolavirus 
 Reston Ebolavirus 
 Sudan Ebolavirus 
 Tai Forest Ebolavirus 
 Zaire Ebolavirus 
Marburgvirus Marburg Marburgvirus 




1.1.4 Ebola; Genome structure and organization 
The EBOV genome is about 18–19 kb in length and encodes for seven proteins: NP, 
GP, RNA-dependent RNA polymerase (L-protein), and structural proteins VP24, 
VP30, VP35 and VP40, as well as the GP splice variants: secreted GP (sGP) and 
small soluble GP (ssGP)21 ( 
Figure 2). 
Experiments have demonstrated that the GP is the only protein located on the EBOV 
surface22. It follows that the GP protein contributes to viral pathogenicity and is para-
mount to EBOV infection. The ebolavirus NP is the largest gene within these non-
segmented negative stranded viruses and plays a central role in viral replication23. 
NP protein in association with VP35, VP40 and L-protein are part of the ribonucleo-
protein complex responsible for virus genome transcription and replication. In addi-
tion, VP24 is thought to be involved in nucleocapsid formation24. On the other hand, 
yang et al demonstrated that NP, VP35 and VP24 are absolutely essential and suffi-






Figure 2: Filoviridae (virion)  
Filoviridae virions are filamentous and in the case of EBOV they are ~970 nm long and about 





1.1.5 Ebola; Replication 
Replication of EBOV takes place into the host cell cytoplasm. Virus entry will start 
when the virion becomes attached to cell surface via specific GP receptors such as 
TIM-1 on the cell membrane. 
Though EBOV encodes for several proteins; only the GP protein determines virus 
tropism and interaction with target cells such as monocytes, macrophages, dendritic 
cells, endothelial cells, fibroblasts, hepatocytes, and adrenal cortical cells25. Notably, 
GP protein is made up of two subunits including GP1 which is the receptors binding 
subunit and GP2 the fusion subunit26. It has been demonstrated that virus binding 
efficiency is enhanced by the activity of acid sphingomyelinase (aSMase) in associa-
tion with the plasma membrane sphingomyelin of the host cell27.  Upon virion attach-
ment to host membrane, several cellular factors including DC-SIGN and L-SIGN are 
implicated in enhanced virus entry into host cell via receptor mediated endocytosis 
mechanisms28. Following its entry into the cell, the virion particles enter into endo-
somes where GP1 is cleaved in the presence of low-pH-dependent cysteine cathep-
sins B and L. The processed GP1 interacts with the late endosomal/lysosomal protein 
Neimann-Pick C1 (NPC-1)29. This interaction results in GP2-dependent fusion of the 
viral envelope with the endosomal limiting membrane of host cell. In contrast, host 
cell deficiency in NPC-1 proteins result in poor binding of the virus which consequently 
may prevent EBOV infection in some patients. Furthermore, the virion fusion also 
requires Two-Pore Channel 2 (TPC2) activity and the role of TPC2 in viral entry is 
not, to date, clearly specified30. In the final stages of virus infection, the viral nucle-
ocapsid is released into the host cell cytoplasm which is then followed by the viral 
genome transcription and translation31. Finally, virus particles are assembled to form 
new infectious viruses which are released via budding into host organs. The viral 
progeny then spread to a variety of target cells resulting in general infection which 
consequently leads to the multiple organ failure (MOF) observed in EVD. 
EBOV genome transcription starts with the binding of the polymerase complex to a 
single binding site located within the leader region of the genome32. The EBOV RNA 
genome, which is dependent on the transcription activator VP30, synthesis seven 
monocistronic mRNAs (encapsidated) that are capped and polyadenylated with pre-
cised length determined by highly conserved start and stop signals. Individual genes 
are then sequentially transcribed into viral proteins along the RNA template following 
3’ to 5’ order using the host cell’s ribosomes and tRNA molecules. EBOV genome 
replication is performed via three proteins including NP, VP35 and L and starts when 
23 
 
nucleoprotein is sufficient to encapsidate neo-synthetized antigenomes and ge-
nomes33. As viral protein levels rise, a switch occurs from translation to replication. 
This phenomenon uses the negative-sense genomic RNA as a template. Further, a 
complementary +ssRNA is synthesized and used as a template for the synthesis of 
new genomic (-) ssRNA quickly encapsidated32. The newly formed nucleocapsids and 
envelope proteins associated with the host cell’s plasma membrane are released via 
budding. Finally, multiple virus release lead to host cell destruction (lysis) which con-
sequently lead to cell death. 
 
1.1.6 Ebola; Disease and immune response 
Reports from previous filovirus outbreaks have demonstrated high mortality rates 
ranging between 30 to 90 % in human and non-human primates according to the virus 
subtype9. EVD starts with high fever >39°C, serious headache and multiple symptoms 
can occur, including abdominal pain, nausea, sore throat, vomiting which becomes 
bloody at the last stage of the disease, and diarrhoea which is responsible for severe 
dehydration. Haemorrhagic manifestations are the last signs and occur when there is 
multiple organ failure (MOF) due to high levels of viral spread throughout the organs 
41. Infected subjects encounter loss of appetite and disorientation which can often end 
with unconsciousness and death 10,41. The initial cells that succumb to EBOV infection 
are myeloid cells (macrophages and dendritic cells), followed by hepatocytes and 
vascular endothelial cells. Early infection of mononuclear and dendritic cells that are 
involved in the immune response are thought to contribute to immune suppression. 
As the disease progresses, parenchyma cells, like hepatocytes and adrenal cortical 
cells are infected, thereby affecting the function of liver and kidneys 41. A massive 
release of inflammatory mediators increases vascular permeability leading to shock 
and disseminated intravascular coagulation which leads to coagulopathy and bleed-
ing1. Finally, the virus may persist for some days in blood, vomit, sperm or sliver, 
though the virus is fragile and is rapidly inactivated when exposed to chlorine disin-
fection, heat, direct sunlight or UV light, soaps and detergents 10. 
Although the human immune system is made up of several physical, chemical, and 
cellular components, it is generally divided into two major groups, the innate and 
adaptive systems. Both systems contribute to protect individuals from a wild range of 
pathogens. As the innate system provides a constant level of physical protection; the 
adaptive system recognises and provides specific protection against microorganisms 
and provides long-lasting immunological memory. Interestingly, both systems work 
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closely together to protect the body against either new invasive or previously encoun-
tered microorganism 34.  
EBOV is one of the most lethal pathogens and to date the interaction of EBOV with 
the human immune system remains incompletely understood35,36. In January 2017, 
the first report was published to show T-cell and B-cell dynamics and antigen-specific 
T-cell response in EVD survivors receiving only supportive care with no experimental 
drugs37. The data combined with other available reports revealed a vigorous specific 
humoral response following EBOV infection and the genesis of neutralizing antibodies 
that could persist weeks after recovery38,39. Severe disease following EBOV infection 
is probably related to an early activation of T-cell responses followed by the produc-
tion of high levels of inflammatory cytokines known as “cytokine storm” which contrib-
ute to coagulopathy, oedema and multiple organ failure 45. Importantly, Agrati et al 
demonstrated that EBOV infection induces sustained CD8+ T-cell activation which 
further leads to the overall decline of functional lymphocytes45. Understanding the 
contribution of human specific immune response to EBOV infection and the effective 
protection or pathogenic responses will effectively improve the development of ther-
apeutics and vaccines. 
 
1.1.6.1 Innate immune response to Ebola virus 
In general, the innate immune system comprises intact skin and mucous membranes 
secretions (enzymes and acids), which essentially protect the body from infection. 
Moreover, an antiviral family of molecules identified as interferons (IFN-α, IFN-ẞ, IFN-
y) provides an important additional line of innate defence to microorganism invasion43. 
Interferons molecules are infected cells products (cytokines) which enhance host pro-
tective defences to eradicate evading pathogens43. They activate host immune cells 
(macrophages and natural killer cells), up-regulate the expression of major histocom-
patibility complex (MHC) for antigen presentation and increase certain symptoms of 
infection such as fever and muscle pain. Consequently, viral replication is inhibited in 
host cells resulting in host protection from viral infection. When physical defence bar-
riers are breached, microorganisms are targeted by phagocytic cells including poly-
morphonuclear cells (Neutrophils, Eosinophils, and Basophils). Firstly, microorgan-
isms are grasped and engulfed by those cells (phagosome), then fused with lyso-
somes which finally release toxic enzymes to destroy them (phagolysosome)43. And 
then inflammatory cytokines are produced to protect neighbouring cells. 
Lue et al. conducted a transcriptomic analysis to determine the host immune re-
sponse to EBOV using messenger RNA expression patterns and this indicated that 
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natural killer (NK) cell populations are abundant in EVD survival patients as opposed 
to fatal cases35. These experiments were carried out on blood samples from Guinea 
EVD infected patients of the 2013-2016 West Africa outbreak. In the event of EVD 
infection, the lack of dendritic cell activation leads to a poor immune response medi-
ated by NK, T and B cells40. As a result, invasive virus outgrowth and spread in host 
organs occurs. Therefore, early activation of the immune responses at all levels is 
critical to limit virus growth and prevent a fatal outcome. NK cells actively respond to 
viral infection by secretion of high levels of cytokine and chemokines such as perforins 
and granzymes which play a key role in infected cell destruction41. The deficiency of 
NK cells or NK cell-mediated lysis due to removal of the inhibitory signals leads to 
host vulnerability to EBOV infection which consequently contributes to an EVD fatal 
outcome49. Nadia et al. investigated EBOV infection in humans and showed that the 
innate immune response is associated with a “storm of cytokines” linked to hyperse-
cretion of numerous pro-inflammatory cytokines including (IL-1ẞ; IL-1RA; IL-6; IL-8; 
IL-15; IL-16), chemokines and growth factors (MIP-1α; MIP-1ẞ; MCP-1; M-CSF; IP-
10; GRD-α and octavin)42. The investigation finally indicates no increase of antiviral 
IFN-α but a massive decrease of peripheral CD4 and CD8 positive lymphocytes and 
established that the Fas/FasL-mediated apoptosis could probably be related to an 
immunosuppression of circulating cytokines produced by T lymphocytes.   
 
1.1.6.2 Adaptive response to Ebola virus 
It is known that the basic components of the adaptive immune system are lympho-
cytes43. These cells originate from stem cells in the bone marrow and are sub-classi-
fied into three groups; lymphocytes T, lymphocytes B and natural killer cells according 
to their origin of maturation. B cells are matured in the bone marrow and are respon-
sible for antibody production whereas T cells complete their maturation in the thymus 
and have antiviral, antifungal, and immunoregulatory functions43.  
 
1.1.6.3  B cells responses to Ebola virus 
A study conducted by Wu et al to determine the nature of the immune response to 
EBOV43 established that the rapid depletion of lymphocytes by apoptosis is a promi-
nent feature of the disease, resulting in the impairment of the host immune response. 
Though the role of antibodies in viral clearance is not fully understood, however some 
findings indicate that antibodies seem to appear as early as day-5 after symptoms 
onset, then rise to peak after two weeks. In the event of recovery, antibody titre de-
clines slowly over years44. The features of human antibody response to ebolavirus 
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GP remain unknown since only a few quantities of monoclonal antibodies (mAbs) to 
GP have been isolated from EVD survivors45,46. B cell response to EBOV GP was 
studied by cloning an extensive panel of mAbs to GP harvested from EVD survivor’s 
peripheral B cells following the 2014 EBOV outbreak in the DRC54. This study showed 
that the B cell response to EBOV is characterised by a broad diversity of clones pri-
marily targeted three non-overlapping antigenic sites: the glycan cap, the GP1/GP2 
interface and the stalk region inclusive of the HR2 helices. Also, the study demon-
strated that a substantial fraction of the mAbs cloned from GP-specific B cells show 
neutralizing activity; therefore, it indicated that neutralising antibodies (Nabs) could 
develop during EBOV infection. Furthermore, experimental research aiming to de-
velop a protective monotherapy against lethal ebolavirus infections established that 
B cell memory specific to EBOV could persist for more than a decade after recovery55.  
 
1.1.6.4 T cells responses to Ebola virus 
An experimental study using a mouse model infected with lethal EBOV demonstrated 
that mice presenting deficient in CD8+ T-cell were overwhelmed whereas, mice defi-
cient in B cells or CD4+ T cells cleared the infection and survived47. The study then 
established that CD8+ T cells play an important role of protecting the host against 
acute disease. CD8+ T cells initially clear the virus while CD4+ T cells were associated 
with antibody mediated protection. Immunophenotyping analysis of acute EVD patient 
samples indicated that the levels of CTLA-4, a negative regulator of T cell activity, 
were significantly higher in CD8+ T-cells from fatal EVD cases compared to EVD sur-
vivors47. Thus CTLA-4 may play an important role in T cell inhibition and in immune 
homeostasis in the context of EVD; however, data to examine the cellular responses 
in EVD supported that a strong antigen-specific T cell response could develop during 
an EBOV infection and demonstrated that EBOV nucleoprotein is largely targeted by 
T cells during human infection46. Furthermore, Julie et al conducted another experi-
ment on mice to demonstrate cytotoxic T lymphocytes (CTLs) mediated protection to 
EBOV44. The study not only reported that CTLs-mediated contribute to protect against 
EBOV but also comment on the need to evaluate viral proteins for protective cellular 
immune responses in the development of effective vaccine strategies. Therefore, to 
develop an optimal and efficient EBOV vaccine, researchers will have to induce a 
combination of protective humoral and protective cellular responses to simultane-





1.1.6.5  B and T cells dynamics 
Despite being the strong line of the cellular immune response to a range of invasive 
microorganisms; data on lymphocyte dynamics and the antigen specificity of T cells 
in Ebolavirus infection are little known. As a result, T and B cells dynamics remain 
incompletely understood.  
In the context of EVD, available human data is lacking but includes a longitudinal 
report45. In 2014, Emory University in USA carried out a study focusing on B and T 
cell activation exploiting blood sample from four EVD patients using phenotypic mark-
ers46. The study described the presence of robust B and T cell responses and estab-
lished the first kinetic data on the activation status of human B and T cell population 
responses in the acute phase of EBOV infection. Another interesting study on an EVD 
survivor who, under medical care, cleared the infection without experimental drug 
assistance showed neutralizing antibodies that persisted almost 5 weeks after recov-
ery47. Additionally, EBOV specific T cells measured in 3 EVD survivors observed con-
sistent IFNy responses to nucleoprotein and multiple responses to GP48. The study 
additionally reported the presence of consistently high T cell activation and a strong 
IFNy response to GP. Furthermore, in vitro experiments on EBOV infection of den-
dritic cells carried out by Mahanty et al indicated that T and B cell function could be 
slightly impaired49. Baise et al have demonstrated a decrease in mRNA levels of IFNy, 
Interleukin 4 (IL-4) and Interleukin 2 (IL-2) and have closely evoked a lack of anti-viral 
immune response at the infection time50. Furthermore, Corti et al using infected hu-
man PBMCs provided direct evidence that EBOV infection causes dramatic cell apop-
tosis in lymphocytes mainly in CD4+ and CD8+ T cells46. The published data indicated 
that 30-40% of the CD4+ and CD8+ T-cells were dead on day 8 following infection.  
While CD4+ T cells are required for IgM to IgG switching and CD8+ T cells are involved 
in EBOV infection control, cytokines play a fundamental role in communication allow-
ing the immune system and host tissue cells to exchange information and to recruit 
macrophages and T cells at the site of infection43. The apoptosis of these cells leads 
to host inability to control virus levels in an ongoing infection. Consequently, the virus 
could rapidly spread in the host organism and causes severe damage which may lead 
to a fatal outcome59.  
Conclusion from the above reports indirectly suggest that EBOV causes massive 
death of human CD4+ and CD8+ T-cells delaying an anti-EBOV IgG response in in-




1.1.7 Host immune response and outcome to survival 
Findings from 2013-2016 EVD survivor samples are providing a deep understanding 
on several aspects of EBOV infection and the human immune response. Though Al-
bumin and fibrinogen proteins are known to be associated with a significant liver pa-
thology; and recent data has reported that during an acute phase, fatal cases show 
strong upregulation of interferon signalling, albumin and fibrinogen genes compared 
to non-fatal individuals35. These studies further identified a small panel of responding 
genes that might intervene as strong predictors of patient outcome, independent of 
autonomous of viral load. Some studies have previously indicated that IL-6 signalling 
has been linked with fatal outcome to EBOV infection57,42. In 2010, the largest study 
ever done on blood samples from 50 volunteers from EVD survivors revealed that 
fatal outcome is mainly associated with an excessive innate immune response. This 
include the hypersecretion of multiple pro-inflammation cytokines and growth factors 
followed by a massive inhibition of adaptive immunity but no increase of IFN-α in 
patients57. A published study has shown that PD-1 ligation inhibits T-cell activation 
only upon T cell receptor (TCR) engagement and interferes with signalling molecules 
like phosphatidylinositol-4,5-bisphosphate 3-kinase and Ras, which are important for 
T-cell proliferation, cytokine secretion and metabolism51. The study indicates that T-
cell exhaustion is mainly characterized by persistent infection. However, long-term 
exposure to viral antigen significantly causes T-cell reprogramming leading to high 
PD-1 expression and T-cell exhaustion52. Almost all evading pathogens have suc-







































Figure 3: Normal cellular immune response to Ebola virus.  
(A) T-cell activation phase: (1) ebolavirus attaches and is engulfed into host cell via GP1/2 
receptors. (2) Lysosomes fuse with late endosome, release enzymes to degrade the virus. (3) 
ebolavirus is dissected into particles. (4) Viral particle (antigen) is presented on the antigen 
This figure used images that were created with Biorender.com and are permissible to use. 
This figure used images that were created with Biorender.com and are permissible to use. 
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presenting cell (APC) cell surface via complex major histocompatibility-2 (CMH-2). (5) T-cell 
binds to APC on CMH-2 receptor via T cell receptor (TCR). This binding is reinforced by CD4 
proteins. (6) CD80/86 binds to CTLA-4 and consequently, (7) APC releases interleukin 1 (IL-
1) to activate T cell. (B) Immune cells activation: Activated cell (CD4+) activates TH-1 and 
TH-2. Activated T cells (TH-1 and TH-2) produces cytokines (ILs, IFNs, TNF, and growth fac-
tors). IL-2 stimulates cytotoxic T lymphocytes (CTL) which produces enzymes for virus lysis.  
IFN-ال stimulates phagocyte macrophages which engulf degraded cells. IL-12 stimulates nat-
ural killer cells (NK). IL-4 activates B cells which produce specific EBOV antibodies. 
 
















Figure 4: Inhibition of cellular immune response to Ebola virus.  
(1)ebolavirus attaches and is engulfed into host cell via GP1/2 receptors. (2) Lysosomes fuse 
with late endosome, release enzymes to degrade the virus. (3) ebolavirus is dissected into 
particles. (4) Viral particle (antigen) is presented on the antigen presenting cell (APC) cell 
surface via complex major histocompatibility-2 (CMH-2). (5) T-cell binds to APC on CMH-2 
receptor via T cell receptor (TCR). This binding is reinforced by CD4 proteins. (6) Anti-CTLA-
4 binds to CD80/86 binds to prevent CTLA-4 binding. (7) Consequently, Interleukin-1 (IL-1) 
production is inhibited leading to T cell inactivation. As a result, the cellular immune response 
is damped. 
 
This figure used images that were created with Biorender.com and are permissible to use. 
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Anja et al evaluated the phenotype of antigen presenting cells (APCs) in the periph-
eral blood of Guinea EVD patients 53. The experiment indicated that there are estab-
lished roles for T regulatory (Treg) cells and the immunosuppressive cytokines IL-10 
and TGF-ẞ in limiting anti-pathogen effector T-cell responses. Therefore, severe dis-
ease in humans affected by EBOV is a result of an important transformation of the 
immune system. Not only did the study identify classical CD14, intermediate CD14/ 
CD16, non-classical CD16 monocytes, activated HLA-DR neutrophils and DCS but it 
also observed a reduction of CD1c DC monocytes and a significant increase of CD16 
monocytes. Finally, the study reported that there is a significant reduction in circulat-
ing monocytes which is associated with EBOV severity whereas; a robust activation 
of CD16 monocytes (APC) is correlated with a survival outcome63.   
John et al indicated that in general EVD fatal outcome is associated with clinical fac-
tors such as fever, weakness, dizziness, diarrhoea, high level of blood urea nitrogen, 
aspartate aminotransferase and creatinine54. The study established a positive corre-
lation between the viral load and the fatal outcome of the disease. It shows that, pa-
tient presenting with fewer than 100,000 EBOV copies per/ml in serum on RT-PCR 
testing had 33% chance of surviving to disease, whereas, those with more than 10 
million EBOV copies per/ml had 94% of succumbing to disease (P=0.003).  
 
1.1.8 Ebola; Reservoir and Transmission 
Bats appear to be the most likely Ebolavirus reservoir (Figure 5); however, there has 
been difficulty in isolating virus or recovering a complete genome which has frustrated 
efforts to conclusively link EBOV to any host species. However, EBOV RNA has been 
isolated in a few specimens of captured fruit bats (Epomops frangueti, Hypsignatus 
monstrosus, and Myonycteris torquata) in Gabon, suggesting that these may be a 
natural reservoir of the EBOV55,56. Moreover, reports have indicated that at least 8 
historical outbreaks in Africa have occurred through zoonotic transmission via direct 
contact with infected wild animals, which seem to be mainly fruit bats and carcasses 
of potential infected non-human primates57,58,59. Between 2002 and 2003, Bermejo et 
al observed the Lossi sanctuary in northwest of the DRC and found a large number 
of unexplained deaths amongst gorillas and chimpanzee populations60. To under-
stand this, twelve carcasses were assayed for EBOV-specific antibodies and nine 
were found positive. In the same period, the virus spread from north to south DRC 
and infected another troop of gorillas killing 91 amongst 95 individuals. Further inves-
tigations to understand non-human primate fatality and EBOV infection were con-
ducted by Rouquet et al including both bordering countries, the Republics of Gabon 
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and Congo61. The investigation identified 98 carcasses of wild animals including great 
apes amongst which 10 gorillas (10.2%), 3 chimpanzees (3.06%) and 1 duiker 
(1.02%) were tested positive for EBOV specific antibodies. With regards to these find-
ings, it is likely that the high fatality rates (75-95%) observed in non-human primates 
exposed to EBOV infection exclude them as a host reservoir.   
A new ebolavirus, Bombali virus (BOMV), has recently been discovered in Sierra Le-
one in free-tailed bats (Chaerephon pumilus)12. In addition, the first evidence of any 
bat carrying EBOV was recently cited in Liberia in a greater long-fingered bat (Min-
iopterus inflatus)62. Studies to isolate LLOV virus in culture and determine whether 
the virus can persist in animals, primarily Miniopterus schreibers bats failed17. As a 
result, LLOV viral pathogenicity and virulence against infection in bats remains un-
known. On the other hand, the high case fatality observed in bats suggest that there 
could be another host reservoir for LLOV virus rather than Miniopterus schreibers. 
Nevertheless, researchers have found EBOV IgG in 3 African bat species (Epomops 
frangueti, Hypsignatus monstrosus and Myonycteris torquata) in central Africa, Ga-
bon and the DRC30. In West Africa, the first evidence of any bat species carrying 
about one-fifth of EBOV genome was recently found in Liberia. Unfortunately, re-
searchers could not isolate the virus itself. The viral genome was found in a greater 
long-fingered bat38. In general, the maintenance and inter-species transmission sys-
tems remain unknown. So, finding more ebolavirus EBOV species will help to under-
stand what makes some pathogenic and others non-pathogenic and provide useful 
information about how to protect population from pathogenic strains. It will also help 













Ebola virus transmission and spillover route from wildlife to human population. 
 
Figure 5: Schematic representation of EBOV transmission.  
(1) Ebola virus circulates in wildlife with an unidentified reservoir. (2) First contamination (index 
case) occur from animal to human through infected animal manipulation (hunting and butchering) 
or consumption. (3) Disease spread in community (primary and secondary infection) from human-
to-human contact via bodily fluids. Highly exposed peoples are household family members and 
unprotected healthcare workers. (4) EVD survivors encounter long effect of the disease such as 













Using caves for shelter, collecting fruit bats guano to fertilize cultural fields, consum-
ing bushmeat and fruit semi-eaten by animals are major routes of human exposure 
to zoonotic infections. Understanding how emerging viruses are transmitted to hu-
mans is essential to identify and prevent practices that promote transmission. To date, 
there is little data with regards to human-wildlife interaction. For the last three years, 
the food and agriculture organisation (FAO) of the United Nation has focused on the 
importance of qualitative analysis of the bushmeat sector for food security in many 
African countries including Guinea63. Unfortunately, findings on community behaviour 
have highlighted the fact that practices vary widely across cultures and regions and 
that information remains insufficient to prevent emerging diseases in specific regions 
and populations. 
Following infection of the index case, human-to-human transmission follows when 
caring for infected patients via feeding, cleaning and often in African cultures prepa-
ration of bodies for funeral practices. Traditional burial rituals (especially in Africa) 
consist of washing and touching the body (even sleeping beside) in order to prepare 
and accompany the dead to his/her ancestors. People touching, washing, dressing 
and sleeping beside the corpse are at high risk of exposure. This was likely a major 
route of transmission during the West Africa outbreak.       
Studies performed with Guinean survivors of the 2013-2016 EBOV epidemic estab-
lished that EBOV viral RNA can be found in semen up to 13 months following clinical 
recovery64. This indicates that the persistence of ebolavirus genome in semen may 
contribute to disease spread, as for that of Nzerekore (Guinea) with sexual transmis-
sion from an EBOV male survivor65. It follows that the major risk factors for disease 
transmission and amplification in communities is likely via household family members, 
healthcare workers, laboratory scientists, travelers from affected areas and, relatives. 
Moreover, re-using medical items without proper sterilization, consulting with infected 
patients, attending health facilities system without gloves and proper hand disinfec-
tion constitute the main source of healthcare worker transmission66. Notably, during 
the 2013-2016 EVD outbreak in West Africa, a total of 881 cases were notified 
amongst healthcare workers leading to 513 deaths in the three main affected coun-
tries (Guinea, Sierra Leone, Liberia)67. Thus, the use of personal protective equipment 
(PPE) including clothing, helmets, goggles and other garments is necessary to protect 
healthcare workers from infections68. The PPE constitutes a barrier between the 
wearer’s body and the work environment which then reduce exposure to hazards. 
Unfortunately, this equipment is not always available in underdeveloped countries 
resulting in healthcare workers exposure to numerous infections. 
35 
 
1.1.9 Age factor in Ebola virus infection outcome 
Though several studies have indicated that the case-fatality rate in EBOV infection 
disease is dominated by different factors including viral genotype, host immune re-
sponse, and bed side care, we found few studies regarding the role of age in EVD 
survival.   
Available records from previous Ebola outbreaks in Africa and notifications on some 
data indicate a lower case-fatality rate in persons under 16 years of age compared to 
elderly people69. Previous findings have noted that children are relatively protected 
against EBOV infection due to limited exposure to EVD patients or due to prohibition 
of funeral activities preparation compared to adults70. Nevertheless, regarding house-
hold contacts, the risk of virus exposure in both adults and children are relatively 
equal66,71. In Africa, elderly people have an important position in societies, which con-
sequently put them on the frontline to EBOV either with sick persons or dead bodies. 
Caring of EVD patients and attending funeral activities is significantly higher in the 
elderly age group67,72. As a result, old age remains the most exposed group to EBOV 
infection. This fact has been demonstrated by Dowell et al after the 1995 Kikwit EBOV 
outbreak. The study indicated that only 27 over 315 EVD patients were under 17 
years old and reported an increase risk of household exposure in adults67.  
 
1.1.10 Co-infection and clinical outcome of EVD 
Co-infections are common amongst EVD patients, and it is relatively unknown if they 
are harmful or beneficial. Malaria (Plasmodium falciparum) co-infection has been as-
sociated with a significant increase in fatal outcome with 2.5-fold odds of death in 
EVD 68. Additionally, a systematic search on EBOV patient samples to understand 
the outcome of EVD associated with P. falciparum load indicated that 87% of patients 
with broad range load (highest reads mapping) of P. falciparum passed away, how-
ever this was similar to that seen amongst survivors73. This finding suggests a non-
additional effect of P. falciparum on the response during EVD. Furthermore, another 
study aiming to show the correlation on the abundance of P. falciparum gene tran-
scripts associated with the coagulation pathway was conducted on 23 Guinean EVD 
survivors by Liux et al 35. In the report, the study indicates an increase of transcripts 
in patients tested positive for P. falciparum compared to those tested negatives for P. 
falciparum and showed the effectiveness of associated antimalarial therapy in EBOV 
treatment. The study also demonstrated through deep sequencing the presence of 
viral nucleic acids, bacteria, fungal, and parasitic organisms in many patient blood 
samples. Those opportunistic microorganisms may be responsible for severe bacteria 
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sepsis, pneumonia or bacteraemia leading to host death. Results from oral swab sam-
ples collected from EVD patients indicated the presence of bacteria such as Neisseria 
meningitidis and fungi which largely contribute to weakened host immune system 74.   
GB virus C (GBV-C), known as human pergivirus, was associated with EBOV during 
the West Africa 2013-2016 outbreak. GBV-C is an immunomodulatory virus which 
attenuates the pathogenesis of HIV. Subsequently, GBV-C co-infection with EBOV 
show no significant survival or fatality outcome in EVD patients examined in Sierra 
Leone75. Finally, understanding co-infection in EVD may lead to new treatments and 
better understanding of immune interactions.  
 
1.1.11 Ebola; Diagnosis, prophylaxis and vaccines 
Early detection of the disease, good supportive care and a strong adaptive immune 
response will help patients recover from the disease66. Rapid diagnostics is one of 
the most important aspects in preventing an EVD fatal outcome. Disease confirmation 
is done in laboratories through detection of the causative viral RNA genome via RT-
PCR. ELISA techniques are used for antibody detection and virus isolation is per-
formed by cell culture76. 
Selective viral inhibitors or neutralizing antibodies, such as ZMapp, can retard or block 
viral entry into host cell81. An identified molecule of benzylpiperazine adamantane 
diamide-derived compound is capable of inhibiting EBOV infection and is currently 
being investigated75. The experiment reported that the inhibitors target is the virus 
endosomal membrane protein which blocks interactions with NPC1, which plays an 
important role in viral membrane fusion. In Guinea, during the 2013-16 outbreak Sis-
soko et al performed an experimental treatment with the viral replication inhibitor, the 
Favipiravir (clinical trials.gov. NCT02329054). Unfortunately, the trial ended with nu-
anced conclusions. No conclusion on the efficacy of the drug was established; how-
ever, it generated understandings about a quick set up and run of Ebola trial in EVD 
foyer 77. Additionally, other experiments have established that a combination of hu-
manized monoclonal antibody (ZMapp vaccine) has given promising result in NHPs79. 
Since the 1980s, EBOV vaccines development has been a global health concern. The 
first EBOV vaccine produced was an inactivated virus vaccine43. Since, multiple vac-
cine platforms have been developed such as: conventional ebolavirus vaccines, 
ebola virus-like particles (VLPs), non-replicating vaccine vectors and, replicating-
competent vaccine vectors52. Presently, the increasing number of ebolavirus vaccines 
in development are most commonly base on GP, NP and VP40 viral proteins. These 
vaccine platforms have demonstrated successful results in protecting NHPs against 
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lethal infection and were advanced to clinical trials in humans52. Notably, rAd26-
EBOV, chAd3-EBOV, rVSV-EBOV and MVA-BN filo vaccines are the most promising 
vaccine candidates for EBOV infection83. ChAd3-EBOV, known as cAd3-EBOZ de-
rived from chimpanzee adenovirus type 3 and expresses ZEBOV and SUDV GP, was 
formally used in trial in the US and Malian adults volunteers for its safety, tolerability 
and immunogenicity87, 84. The experiment documented that 1 x 1011 pfu of ChAd3-
EBOV is well tolerated and could boost an antibody titer that could protect against 
wild-type EBOV infection. Finally, the experiment suggested that ChAd3-EBOV is ef-
fective to terminate Ebola virus transmission and consequently protect household 
family members and relatives. Currently, on-going clinical trials involving chAd3-
EBOV and rVSV-EBOV are in progress but not yet published83. Trials feature the 
United Kingdom, the United States of America, Switzerland and some African coun-
tries. On the other hand, an FDA approved Ebola Zaire vaccine ERVEBO (rVSV 
ZEBOV) has been used in the current DRC outbreak since December 201980.  
The licensed vaccine ERVEBO is an attenuated vesicular stomatitis virus with its host 
glycoprotein replaced by an EBOV GP gene. To date, rVSV-based vector is being 
used as a promising live virus vaccine candidate for a panel of viruses including in-
fluenza virus, human immunodeficiency virus, and bovine viral diarrhea virus88,89,90. It 
is then obvious to conclude that in an outbreak event, ring vaccination should inclu-
sively include local medical staff, family members and close contact relatives as the 
most appropriate strategy to go forward infection eradication.  
 
1.2 The West African EVD Outbreak of 2013-2016  
The West Africa EVD epidemic has been the largest to date resulting in numerous 
deaths and social unrest13,91. The outbreak is thought to have originated during De-
cember 2013 in a small village called Meliandou in Gueckedou (Republic of Guinea) 
and was confirmed in March 2014 (Figure 6).  
The index case was reported to be a 2-year-old boy and was related to a zoonotic 
transmission, probably, from bats92. In the beginning, the unknown disease was con-
sidered as a mysterious event. It quickly spread to the nearest prefecture Macenta 
and eventually reached the capital city, Conakry. First samples were collected from 
deceased patients in Macenta and sent to Europe where it was confirmed to be EBOV 
pathogen. Unfortunately, the epidemic spread to the neighboring countries Liberia 
and Sierra Leone via land borders. In a short period of time, the disease was notified 
in other countries such as Mali, Senegal and Nigeria. Several efforts were made by 
partners (international organisations) and national teams to contain the epidemic. The 
38 
 
last WHO report on June 10, 2016 revealed 28,616 confirmed cases amongst which 
11,310 deaths occurred13. The report stated that the West Africa ebolavirus outbreak 
was the longest, largest, deadliest and the most complex ebolavirus outbreak since 
the discovery of the virus in 1976. Previous EVD outbreaks in Africa have been linked 
to Zaire, Uganda or Sudan EBOV strains and the 2013-16 West Africa epidemic was 
thought to be from the Zaire Ebolavirus (EBOV-Mayinga) strain14. But the strain was 
later named Makona (EBOV/Mak) after the Makona river bordering the three main 
affected West African countries. The Makona river originates from Guinea (Makona 
means bitter in the local language of the Toma tribe), passes through Liberia and 
Sierra Leone and ends in the Atlantic Ocean. The EBOV/Mak strain encountered dif-
ferent mutations (lineages) in Guinea (GN1, GN2, GN3, GN4), Sierra Leone (SL1, 
SL2, SL3) and Liberia. These lineages were all linked to the initial lineage first notified 
in Guinea93. Jeffrey et al sequenced Liberian EBOV/Mak positive samples and ob-
served 23 nonsynonymous mutations and 1 nonsense mutation94. The study finally 
reported that at least 33 viral mutations occurred during the West Africa ebolavirus 
outbreak. In addition, EBOV GP mutant GP-A82V was found to be located at the 
NPC1 binding interface and could possibly be responsible for high infectivity in human 
cells95. 
Marzi, et al investigated the similarity between the two strains of EBOV, Mayinga and 
Makona96. Both strains were inoculated into Cynomolgus macaque models to com-
pare their pathogenic effects and it was reported that EBOV/Mak infection disease 
progressed slower than EBOV-Mayinga and the experiments showed a high case 
fatality rate in EBOV/Mayinga (≈90%) compared to EBOV/Mak (≈50%). In contrast, 
major release of IFN was notified in EBOV/Mak individuals compared to EBOV/May-
inga subjects.  
In Guinea, by the end of September 2016 there were 3,358 confirmed cases and 
2,088 deaths amongst which 115 were healthcare workers. In the Macenta prefec-
ture, located in Forested region of Guinea, a total of 714 confirmed cases were re-
ported with 467 deaths97. Unfortunately, there are no publications on two cases of 
suicide likely due to both sexual dysfunction and stigmatization. Investigations on the 
long-term effects currently seen amongst EVD survivors will bring more understand-
ing about the disease in Gueckedou. Common side effects include ocular pain, pho-
tophobia, renal and sexual disfunction, amenorrhea and trouble of vision. Neverthe-
less, ebolavirus persistence was studied in some Guinean male survivors following 
the outbreak64. RT-PCR was performed every three months to determine the pres-
ence of viral RNA in sperm and the study report established that viral RNA is detect-
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able in the sperm at least 13 months after recovery. Although, a similar study per-
formed on MARV survivors indicated that MARV RNA could persist 3 months after 
the onset of the disease66. Therefore, survivors from both ebolavirus and mar-
burgvirus should be provided and instructed to use condoms during the convales-
cence period in order to avoid sexual transmission. The last case of the West Africa 
ebolavirus disease outbreak was known to be from a sexual transmission. It was no-
tified in Guinea after 3 community deaths in Nzerekore region at Koropara subprefec-
ture and later spread in Liberia. The virus might have persisted in seminal fluid for 
about 531 days after recovery and was transmitted in February 2016 via sexual inter-
course65.  
 
The starting point of the West Africa EVD outbreak 
 
Figure 6: Meliandou Village 
Meliandou village shown by the red dot is in West Africa in the Republic of Guinea. Lat/Long 
8°37’20’’ N10°03’51.1’’W. From https://probaway.files.wordpress.com/2014/10/meli-
andou_map.jpg . Meliandou village, the starting point of the West African 2013-2016 EVD huge 









1.2.1 West African Outbreak management 
The 2013-16 ebolavirus outbreak in West Africa illustrates the potential for epidemics 
to emerge from a single zoonotic transmission. In the three affected countries, local 
government authorities and international partners effectively acted to halt the epi-
demic. The outbreak started with early mistakes including poor dissemination of in-
formation about the disease from inexperienced persons (e.g. media), political mis-
trust of local governments and opposition parties98. Other elements of the disease 
spread could be associated to poor healthcare systems, bad infrastructures and un-
trained healthcare workers in affected countries. These factors seriously contributed 
to the spread of the disease. While local government thought about population ma-
nipulation by opposition parties; opposition parties accused local government of in-
venting new strategies to avoid presidential elections planned in the year 2015 in 
Guinea and Sierra Leone. Political considerations, local government’s unclear posi-
tion, and population mistrust lead to hamper international efforts. Moreover, the 
spread of the disease was also thought to be planned by leaders of the three affected 
countries Guinea, Liberia, and Sierra Leone to raise money from worldwide organi-
zations. As misunderstandings took place, the disease kept spreading rapidly to be-
come an uncontrollable crisis of international level. The large population base, grow-
ing trade business between countries via land borders and health system inexperi-
ence regarding the disease all contributed to the spread of EVD in West Africa.  
The causative agent of the outbreak was simultaneously identified to be ebolavirus 
(EBOV Zaire strain) at P4 laboratories respectively in Lyon (France) and in BNI (Ger-
many) by polymerase chain reaction (PCR)99. On March 23, 2014 WHO declared the 
epidemic as an international concern91,92. It followed that local governments, partners, 
and NGOs actively promoted information about the disease via illustrations, fact 
sheets, videos and, posters. Although, healthcare systems improved through con-
struction of treatment centres, isolation systems, rapid diagnostic (RT-PCR and se-
quencing) and staff training. Additionally, local communities successfully got involved 
via multiple outreach on securing funerals and burials and contact tracing. Interna-
tional interventions include clinical trials (JIKI, ZMAP)77; experimental treatment (in-






1.2.2 Social impact of the West Africa EVD 
The impact of EVD on public health systems, economic and social life in Guinea, 
Liberia and Sierra Leone was seismic. It brought fear and paranoia to the population. 
People (workers or traders) were immobilized or moved from affected areas to unaf-
fected areas to avoid transmission. Schools, training centres, enterprises and busi-
nesses temporarily or totally closed causing loss of jobs and education. Fear and 
stigmatization toward survivors of the disease was common. As a result, some cul-
tures were broken, extended family meetings avoided, and ceremonies restricted. 
Discharged patients (survivors) and family members were banned from attending 
public assemblies. In some places, this exclusion provoked mental problems in some 
individuals leading to suicide as for that of Gueckedou (no reported). 
High infection rates amongst close contacts, relatives and healthcare workers, signif-
icant case fatalities in patients attending healthcare facilities, and finally a lack of cu-
rative treatment contributed to increase fear and distress in the population. These 
effects acted to considerably reduce health facilities attendance in affected areas. 
Fear, mystery, paranoia and unfamiliarity related to the disease often provoked pop-
ulation movement and, consequently, medical staff were reluctant to assist patients 
or return to regular duties in healthcare facilities14.  
Furthermore, emotion and ignorance lead local people to perceive that healthcare 
centres and partners including NGOs and international organizations were responsi-
ble for spreading the virus. As a result, common tropical curable diseases such as 
malaria were not treated resulting in more deaths than the filovirus itself. Field inter-
vention groups from national authorities and partners added to community fear and 
distress when wearing full personal protective equipment (PPE) and while carrying 
patients or disinfecting zones. Also, previous outbreaks have come to prove that mul-
tiple and diverse media attention including bad reporting from unexperienced and un-
informed persons about the disease contributed to fear and distress. This resulted in 
resistance due to population mistrust and made it difficult to control and sustain the 
epidemic. Finally, stigmatization behind EVD left affected individuals (widows and or-








1.3 Sub symptomatic infections 
Sub-symptomatic and asymptomatic infections are defined as infections with com-
plete absence of clinical symptoms whereas, pauci-symptomatic is an infection with 
minimal symptoms101. Detecting asymptomatic infection early is important to prevent 
disease and infection spread. Asymptomatic persons can be a carrier of the disease 
and constitute high risk to vulnerable people, therefore, asymptomatic persons should 
be diagnosed and treated so that future medical problems and infection transmission 
can be avoided.   
In general, asymptomatic infections are often discovered when subjects undertake 
medical tests either for research proposes or in hospital admittance conditions asso-
ciated with another disease occurrence. One of the major problems with asympto-
matic infections such as HIV/AIDS and cytomegalovirus is a weakening of the im-
mune system or damage to tissues and organs101. Consequently, people become 
vulnerable and susceptible to opportunist co-infections. For example, human immu-
nodeficiency virus (HIV) causes severe systematic T cell (CD4) destruction which re-
duces cell-mediated immunity102. Therefore, a wide range of opportunistic infections 
and cancers can occur followed by tissues damages (e.g. brain) and systemic organ 
damage (e.g. chronic cardiovascular, hepatic). Notably, asymptomatic infections are 
silent therefore, people are unaware about serious medical problems. In a recent 
study published on zika virus (ZIKV) it was reported that 3.2% of asymptomatic ZIKV 
infections were found among pregnant women (n=1116) during 2016 in Cajamarca 
(Peru-South America)103. Another prospective study carried out in India reported that 
the incidence rate of asymptomatic leishmaniasis cases progressing to symptomatic 
cases in humans was about 3.3%104. In addition, Human cytomegalovirus (HCMV) is 
known to be one of the most common asymptomatic infections around the world105,106. 
The HCMV is known as a major cause of childbirth defects. HCMV is also noted as 
the responsible agent for permanent neurodevelopmental disability in children which 
leads to intracranial abnormalities including calcifications and polymicrogyria in in-
fants with congenital cytomegalovirus infection107. Finally, findings on HCMV infec-
tions have established that the infection could become life-threating and causes im-
mune system failure, systemic organs injuries and possibly inhibition of cell death 
over time, leading to various cancers106,107.   
Asymptomatic infection should be also considered in the context of Ebola virus infec-
tions as a public health concern and symptomless people constitute potential reser-




1.3.1  Potential reason for sub -symptomatic infection 
As previously described, filoviruses (e.g. Marburg and Ebola virus) are potentially 
dangerous and cause severe haemorrhagic fever disease in human and non-human 
primates (NHPs). Research on filovirus asymptomatic infections in humans could 
help to understand occurrence and contribute to control the spread of disease.  
When exposed to a pathogenic agent, there are two possibilities. Either the infection 
progresses toward disease with apparent signs and symptoms or toward cure with no 
symptoms. In the event of the asymptomatic situation, the infection progresses with-
out symptoms therefore, a pathogenic agent could be more easily transmitted as the 
infected person who is still mobile and has no knowledge of their infectious status. 
 
1.3.2 Historical Filovirus sub symptomatic infection 
Since its discovery almost 40 years ago in Germany in the city of Marburg and Yugo-
slavia in 1967, MARV has been associated with several haemorrhagic fever out-
breaks in humans and non-human primates with a high rate of mortality up to 90%108.  
Studies in Central Africa (Gabon and Republic of Congo) indicate a fruit bats, 
Rousettus aegyptiacus, to be the potential reservoir of the Marburg virus109. Specific 
viral RNA and IgG antibody were identified in those bats’ species with no apparent 
signs or symptoms. unfortunately, there are few available publications regarding Mar-
burg virus asymptomatic disease infection.  
In 1999-2000, the first non-imported MARV outbreak occurred in the DRC in Durba 
region at Watsa Town110. Following the outbreak, a sero-survey study to identify pos-
sible asymptomatic patients among household contacts was conducted in Watsa sub-
district. A total number of 124 direct contacts of 73 affected households participated 
in the survey. Blood samples were collected, and anti-MARV IgG detection was per-
formed by ELISA. Two volunteers known to have presented symptoms but were not 
laboratory tested were reported to be seropositive. Unfortunately, no serologic evi-
dence for asymptomatic or mild MARV infection was reported. Furthermore, in 2003 
in the DRC, another survey to assess risk factors for Marburg haemorrhagic fever 
revealed 2% of seropositivity for Marburg immunoglobulin G antibody111. To conclude, 
asymptomatic Marburg virus infection is not well understood due to a limited number 
of available documentations compared to ebolavirus infection. 
With regards to EBOV, it is one of the most virulent pathogens in the Filoviridae family 
with a fatal outcome from 7 days onset of the disease73,112. However, minor cases of 
EVD may not be recognized if there are no associated symptoms50. Infected subjects 
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possibly remain sub or asymptomatic due to a low viral infectious dose or a strong 
antibody response to the virus. 
Work on 24 close contacts of EBOV RT-PCR positive subjects in Gabon following the 
1996 EBOV outbreak revealed 11 asymptomatic cases (45.83 %)50. In this study, 
blood samples were collected 4 times within a month from exposed individuals to 
EBOV infected people. Both asymptomatic individuals (close contacts) and sympto-
matic people (EVD confirmed) were included in the study. ELISA and Western blot 
tests were successively performed for EBOV antigen specific antibodies (IgM and 
IgG) detection. Additional investigation included the determination of different cyto-
kines and chemokines. Extracted viral RNA from individuals’ peripheral blood mono-
nuclear cells (PBMCs) were amplified and sequenced. Interestingly, asymptomatic 
individuals 45.83% (11 of 24 asymptomatic people) show both IgM and IgG re-
sponses to EBOV antigen. In addition, Western blot test indicated that IgG response 
were oriented to VP40 and to the NP. In contrast, VP24 and the GP showed no nu-
cleotide differences regarding both symptomatic and asymptomatic individuals. No-
tably, the search demonstrated the presence of strong inflammatory response char-
acterized by massive circulation of cytokines and chemokines in asymptomatic indi-
viduals. Finally, these results strongly demonstrated the evidence of possible asymp-
tomatic occurrence of EBOV infection in individuals which might not necessarily be 
related to viral mutations.  
Mulangu et al investigated EBOV infection in a large population base (n=3415) in the 
DRC and found that 11% showed anti-EBOV IgG113. The study revealed high sero-
positivity in males aged over 15 and provides strong evidence that unrecognized 
EBOV infection has been circulating in the population. In addition, Mulangu et al stud-
ied the seroprevalence of EBOV in Efe pygmies in DRC to determine the possible 
circulation of the virus within this population114. In total, 300 participants (aged over 
10 years) volunteered for the study. The Efe population is known to be highly exposed 
to EBOV through their daily activities such as bushmeat hunting and manipulation, 
entry into caves generally hosted by fruit bats, and contact with diverse wildlife. Col-
lected samples were assayed by ELISA for IgG to EBOV. Efe pygmies were found to 
be highly exposed to EBOV with 18.7% seropositivity with no link to a particular ac-
tivity or contact with wildlife. This seroprevalence to EBOV was known to be the high-
est ever reported. It is unfortunate that the nature of this exposure was not estab-
lished. Moreover, in 1983, a published serological and epidemiological survey in 
Cameroon, Central Africa among healthy rain forest farmers (n=1517) showed a pos-
itive rate of 9.7% to EBOV115. The study included volunteers from five regions and 
blood samples were tested using indirect immunofluorescence assay. With regards 
45 
 
to the data produced, it was confirmed that EBOV has been circulating in those re-
gions of Cameroon with mild or no clinical cases mainly amongst young adults fully 
involved in bushmeat hunting and manipulation.  
Furthermore, Leroy et al conducted a serological survey to determine ebolavirus prev-
alence in nonhuman primates troops (chimpanzees) in Cameroon, Gabon, and 
DRC116. The study involved 790 NHPs from 20 different species. Samples were as-
sayed by ELISA to determine EBOV specific IgG antibodies. The data indicated 
12.9% of seropositivity to anti-EBOV in wild-born chimpanzees and that EBOV-spe-
cific IgG was detected in five species of NHPs including Drills, Baboon, Mandrill, and 
Cercopithecus as well. Finally, the report established that EBOV broadly circulates in 
Central Africa and that the virus was present in some places prior to first outbreak in 
human. Also, it demonstrated the possible occurrence of asymptomatic EBOV infec-
tion in NHPs 
These findings demonstrate that ebolaviruses have been circulating in human and 
non- human primate in multiple locations throughout Africa. In particular, the detection 
of EBOV-specific antibody in NHPs might lead to more investigations to define the 
virus reservoir probably in NHPs. Considering these results, it follows that EBOV out-
breaks may occur anywhere in Africa. So, action should be taken regarding popula-
tion awareness on EBOV to prevent future outbreaks.  
 
1.3.3 Case studies on Ebola virus asymptomatic transmission 
Understanding the context of asymptomatic transmission is important to contain and 
prevent outbreaks. Results from previous studies in the context of ebolavirus as re-
viewed by Heeney 2015117 demonstrate that more work is needed to understand the 
triggers that result in virus persistence and re-emergence. Work performed by Sis-
soko et al. reported that a breast-fed female infant of 9 months died after succumbing 
to EVD, probably infected by her asymptomatic mother118. Guinean authorities were 
first notified of the case in the fall of 2015 and no epidemiological link could be estab-
lished. Investigations show that both the mother and the father did not develop de-
tectable symptoms of EVD, and RT-PCR tests indicates no viral RNA in their blood 
samples. However, further analysis of bodily fluids revealed EBOV RNA in both the 
mother’s breast milk and the father’s seminal fluid. Molecular epidemiological tracing 
indicates that the virus from the child and the mother belonged to the Sierra-Leone 3 
(SL-3) lineage and clustered to the large Conakry-Dubreka circulating sub-lineage 
strain. It was then concluded that the virus might have circulated from the mother to 
the child via breast feeding. Further, sequence analysis of mother and father RNAs 
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suggested that the virus from the mother came from the father without classical symp-
toms. Another breast-feeding infection was notified in Guinea by Nordenstedt et al119 
, in this study a certain pregnant woman who formally cared to her EVD suffering 
mother (unfortunately the mother died) gave birth to twins and a few days following 
the birth, one of the twins passed away presenting with general symptoms of EVD. 
Unfortunately, no PCR test was performed prior to the burial. Afterwards, the mother 
was suspected to have EVD-like symptoms such as fever and headache. She was 
then admitted to an EVD treatment center with her second baby and tested positive 
to EBOV using RT-PCR test. The breast feeding was immediately stopped and fortu-
nately, the baby stayed EBOV negative and was released after two PCR negative 
results. In addition, another study was performed in Guinea on two cases of infant 
transmission through breast feeding, where mothers were tested positive to EBOV by 
RT-PCR120. In the first case, the mother (approximatively 30 years) and child (six 
months infant) were both admitted to the Ebola treatment center (ETC) at Gueckedou 
(Guinea). The mother’s blood, urine and breast milk were all tested on RT-PCR and 
only the urine test showed positivity to EBOV. As the mother’s breast milk was tested 
negative breastfeeding continued. Fortunately, the mother recovered and was re-
leased from the ETC after two RT-PCR negative tests on her blood. On the other 
hand, the child’s blood was tested positive to EBOV and he later passed away. In the 
second case, a woman of about 20 years was admitted to the ETC a week after child-
birth. She was blood tested positive to EBOV on RT-PCR. The breast feeding was 
immediately stopped, and the child separated. Unfortunately, no RT-PCR test was 
performed on her breast milk. On the other hand, EBOV RT-PCR was negative on 
the child’s blood after a sudden onset of fever.  Fortunately, the mother recovered 
and was released after two RT-PCR negatives on her blood and happily the child 
never developed EVD. The study concluded that when caring for mother-child pairs 
in the event of EVD, potential attention of testing bodily fluids such as breast milk and 
urine in addition to blood test should be considered due to the possibility of prolonged 
EBOV shedding in those fluids.  
Furthermore, the transmission of EBOV via breast feeding was also commented upon 
when sequencing samples from both mother and child found positive to EBOV in Si-
erra Leone121. Unfortunately, transmission via breast milk was uncertain as no blood 
testing was earlier performed for the mother and both mother and child were close 
contacts to an EVD confirmed patient. The fact that the mother (who was asympto-
matic) had her breast milk tested twice positive to EBOV and that the child (who was 
symptomatic) was actively breastfed suggested that the child might have been in-
fected by the mother through breastfeeding. These findings conclude that EBOV can 
persist in breast milk and possible transmission may occur via breast feeding. Further 
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investigations should be undertaken to determine the duration of the virus in breast 
milk.   
In Guinea, Daouda et al conducted a longitudinal study on men identified as EVD 
survivors. The study enrolled 26 volunteers to evaluate the dynamic of EBOV persis-
tence and clearance in seminal fluid64. Samples were collected every 3 to 6 weeks 
and tested for EBOV RNA via RT-PCR until two negative results were simultaneously 
confirmed. The study revealed that ebolavirus RNA could persist in seminal fluid for 
up to 13 months after being discharged. In addition, an example of possible sexual 
transmission was reported in the past West Africa EBOV outbreak in Guinea. The 
case was notified and reported to WHO following three epidemiological linked com-
munity deaths65. The new cluster started at Nzerekore region in Koropara sub-pre-
fecture and later spread to Liberia. Reports concluded that the virus could have per-
sisted in seminal fluid for approximately 470 days following discharged from the treat-
ment center and might be sexually transmitted during February 2016. In total, eight 
community deaths occurred, and the case fatality ratio was reported as 80%.  Alt-
hough, the Sierra Leone health ministry and partners, including WHO and CDC, con-
ducted another study amongst EBOV disease male survivors of Sierra Leone122. The 
survey generated a cohort of 220 volunteers to investigate the duration of EBOV in 
seminal fluid. Samples were tested by RT-PCR for several months following dis-
charged from the treatment centre. The study established that the shortest time to 
carry EBOV RNA in seminal fluid was approximately 100 days (3.3 months) and the 
longest time was about 500 days (16.7 months). In addition, Prof. Kader and his team 
conducted a cross sectional study on sex practices and awareness of EBOV disease 
among male survivors and their partners in Guinea (Coyah prefecture)123. The survey 
included a total of 234 survivors, 256 sexual partners and 65 control group individuals. 
It was concluded with strong recommendation that: ‘’sexual health interventions, in-
cluding counselling services in the presence of sexual partners, become an integral 
component of survivors post discharged follow-up to minimise probable sexual trans-







1.3.4 Pros and cons of seroprevalence studies 
Seroprevalence studies are often used to determine prior exposure to a pathogen. 
Detecting asymptomatic infection via molecular diagnostics such as RT-PCR gives 
us definitive proof that an individual has a viral infection. However, seroprevalence 
studies conducted using ELISA based methodology, will give a retrospective view on 
prior exposure to a pathogen. This exposure may be recent or years ago, therefore, 
even when combined with subjective health questionnaires seroprevalence studies 
might not be fully reliable in ascertaining the provenance of asymptomatic infection. 
However, they may contribute to information on disease burden in a community and 
help to identify, support, and prevent infection spread in healthcare settings124. Addi-
tionally, there is a fact that wild antibodies might cross react with the protein of interest 
and this would generate false positive data. 
In conclusion, it is probable that EVD may, in some cases, has resulted in sub clinical 
or asymptomatic infection, and both low infection dose and strong innate immunity 
could have successfully helped patients to remain disease free. Our study aims to 
determine the circulation of ebolaviruses in the forested region of Guinea among 
highly exposed individuals (bushmeat hunters and their household members). These 
people are in daily contact with wildlife animals including several kinds of fruit bats 





1.4 Lassa virus; Introduction 
Lassa virus (LASV) is an Arenaviridae family member which represents a large group 
of viruses that cause persistent infections in human and NHPs (Table 3)125. Infections 
are usually asymptomatic and transmission to human or NHPs occurs through con-
tact with the virus reservoir. The Arenaviridae family is divided into three genera 
(Mammarenavirus, Reptarenavirus and Hartmanivirus) and is composed of two major 
subgroups including Old World viruses (Lassa and Lujo virus) and New World viruses 
(Junín, Machupo, Guanarito, Sabia and Chapare virus)126,127.  
For the last 30 years, LASV hemorrhagic fever has been broadly studied. Neverthe-
less, new discoveries in viral pathogenesis, and advanced diagnostic techniques 
have recently progressed128.  
To conclude, it is wildly known that Lassa virus transmission occurs from rodent to 
human and the disease spreads in community from human to human via close contact 
with bodily fluids. LASV is an emerging virus which needs to be handled in biosafety 
level 4 containment. 
 
Table 3: Arenaviridae family; Genus, viruses 
Family Genus Viruses 
Arenaviridae Mammarenavirus Old World Arenaviruses 
   Lassa virus (LASV) 
   Lymphocytic choriomeningitis (LCMV) 
   Mopeia virus (MOPV) 
   
 
New World Arenaviruses 
   Guanario virus (GTOV) 
   Junin virus (JUNV) 
   Machupo virus (MACV) 
   Pichinide virus (PICV) 
   Pirital virus (PIRV) 
   Sabea virus (SABV) 
   Tacaribe virus (TCRV) 









1.4.1 Discovery of Lassa virus 
LASV disease was first identified in 1969 in Nigeria at Lassa village, hence its 
name129. The disease was notified in a nurse working at Jos missionary hospital in 
Nigeria130. Later, the virus was isolated from the affected nurse who subsequently 
survived with thorough medical support in the United States. Lassa fever is an animal-
borne or zoonotic acute viral disease endemic in West Africa particularly in Nigeria, 
Sierra Leone, Liberia and Guinea131,132. In contrast, the disease seems to be mild or 
undiagnosed in neighboring countries Cote d’ivoire, Ghana, Togo and Benin. How-
ever, the presence of the virus reservoir, the Natal multimammate mouse (Mastomys 
natalensis) and a few isolated cases indicate the circulation of the virus in those coun-
tries92. The virus is responsible for about 100,000 to 300,000 human infections a year 
with approximately 5000 annual deaths91. To date, the only virus reservoir known is 
M. natalensis which is largely distributed in West African countries.  
In Nigeria, Lassa fever is endemic. The disease is confirmed in about 6% of febrile 
adults and 3.5% of febrile children when admitted to hospitals133. Recently, Nigeria 
health authorities have reported a case fatality rate of 24 - 33% in tertiary hospitals. 
In contrast, despite the seriousness of the disease, it is reported that Lassa fever 
control in Nigeria has been widely neglected131. Though several efforts have been 
deployed at all levels including international partners and local government; however, 
Lassa fever remains a major public health concern in the country. From January to 
March 2018, Nigeria experienced its largest outbreak with a total of 1,893 cases re-
ported amongst which 423 were laboratory confirmed with 106 deaths (case fatality 
rate 25.1%)94.  
In Guinea, Lassa fever is infrequently observed. The last confirmed case occurred in 
September 2018 in Mamou. The subject was known to have originated from the 
Southern region of Guinea at Kissidougou town. Fortunately, early diagnostic and 
rapid intervention through contact tracing and follow up successfully contained the 
disease134. Moreover, past sero-surveillance studies on Lassa fever disease, con-
ducted in Guinea, established population exposure to the virus135,136. Bausch et al 
investigated the epidemiology and clinical presentation of the Lassa fever in Guinea 
in 2001. Lassa fever suspected cases were tested using an ELISA platform for anti-
body detection and the analysis indicates 7% of positivity out of 311 samples 
tested137. Additionally, a total of 1616 small rodents (956 Mastomys sp.) captured in 
444 households in the savanna, mixed savanna-forest and forest region of Guinea 
were studied for Lassa virus antibody and antigen detection135. The study results re-
spectively show 11% and 5% of antibody and antigen detection in M. natalensis ro-
dents. Moreover, in 2006, Koivogui et al found up to 55 %  seropositivity to LASV 
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amongst murid rodents population of 13 genera from 8 different localities in Guinea132. 
Another study to estimate the prevalence of Lassa IgG in human population of rural 
area of Guinea including Gueckedou, Lola and Yomou (Southern region) indicates 
12.9% positivity in humans with no prior report of Lassa fever disease136. 
 
1.4.2 Lassa; Species and Phylogeny 
LASV is an RNA virus of the Arenaviridae family, it has a negative-sense, single 
stranded RNA viral genome 128,129. The viral RNA is enveloped, bi-segmented and 
possess both large and small genome section. Formally, four strains of LASV line-
ages were identified amongst which three were identified in Nigeria (GA391, AV and 
LP) and one in Sierra Leone, Liberia and Guinea 138. Presently, based on the geo-
graphical limitations and the new virus strain discovery, LASV strains have been clas-
sified into six lineage groups 139. Lineage I identified in 1969 mainly occurs in North-
eastern Nigeria; Lineage II was isolated in South-eastern and South-central of Nigeria 
(Irrua, Ekpoma, Abakatti, Aba); Lineage III strains are found in North-central of Nige-
ria; lineage IV was isolated in Sierra Leone, Liberia and Guinea; Lineage V is from 
Mali, Ghana and Cote D’ivoire and Lineage VI was found in Togo in 2016. Notably, 
few genetic diversities result in lineages diversification. Especially, antigenic differ-
ences have been noted between Nigeria strains and mano river union strains140,138. 
Although, a single strain of LASV found in Sierra Leone and Liberia was genetically 
different from two strains found in Guinea regarding RNA fingerprinting compari-
son140. In addition, remarkable sequence dissimilarity in NP region was noted be-
tween Nigerian strains and the Sierra Leone Josiah strain and between two Nigerian 
strains141.  
 
1.4.3 Lassa; Genome structure and organization 
LASV belongs to the Old-World complex of the Arenavidae family. The virus genome 
contains two RNA segments (large and small) which encode for two proteins in op-
posite directions resulting in four proteins in total. The large segment  (L RNA, 7 kb in 
length) encodes for the small matrix protein Z and the RNA polymerase L (200 
kDa)142. The small segment (S RNA, 3.4 kb in length) encodes for nucleoprotein NP 
and the surface glycoprotein precursor GP143. The coding strategy is named am-
bisense and the genome replication and transcription require the action of NP and L 
protein144,145. Based on the genome structure, the RNA-dependent RNA polymerase 
(RdRp) is located in the central region of L protein146. And it mediates the synthesis 
of two RNA species including mRNA and antigenomic RNA which represent the full 
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copy of the genome. Findings in Arenaviridae family established that the L protein 
encounters two binding sites of the Z protein respectively in the N terminus and in the 
RdRp147. Finally, regarding its large size and key role in viral replication and transcrip-
tion, it has been indicated that L protein comprises four domains or regions148.  
Laboratory scientists in Germany isolated and sequenced LASV from the first ex-
posed subject outside Africa, in a German funeral home worker149. The virus was 
cultured in Vero E6 cells and viral RNA was extracted using a RNeasy Qiagen minit 
kit. The isolated viral RNA library was sequenced on the Illumina MiSeq platform us-
ing v3 chemistry and paired-end sequencing (2x300 cycles) aligning the sequence 
reads to LASV L and S segments. The results show a coverage of 165x (median 145 






Figure 7: Lassa Virus structure 
Lassa virus possess a negative strand bisegmented RNA genome. It encodes four viral pro-
teins including GP/NP (S segment) and Z/L (L segment). Z protein shown as a small ring plays 
a central role in viral assembly and budding. The membrane glycoprotein GP-C is cleaved into 
two subunits including GP-1 which interacts with cellular receptor α-dystroglycan and GP-2 






1.4.4 Lassa; Replication 
Like in most common viral infections, virus attachment and entry into host cell cyto-
plasm is the determinant of potential disease occurrence and viral replication cycle. 
It follows that Lassa virus transmission occurs when the virus is transmitted from the 
rodent M. natalensis to human. Lassa virus attaches and enters host cells via recep-
tor-mediated endocytosis. Unfortunately, to date, the real endocytosis pathway is not 
clearly defined. Nevertheless, the cellular entry is known to be highly sensitive to the 
decrease of cholesterol in host cell membrane150. Dystroglycan protein is expressed 
in most cells for tissues maturation. This protein is later divided into beta-Dystroglycan 
and alpha-Dystroglycan which is used by LASV receptors for cell entry150. Genome 
replication and transcription will then start in the host cytoplasm where fusion occurs 
at low PH. When the virus enters host cell through α-Dystroglycan mediated endocy-
tosis, viral ribonucleoprotein (RNP) complex is released into the cytosol and the viral 
genome RNA is released. These phenomena occur as both S and L RNA segments 
produce simultaneously the antigenomic S and L RNAs. Both genomic RNA and an-
tigenomic RNAs are actively involved in the transcription and translation process and 
serve as template for viral mRNA transcription151. It follows that new viral proteins are 
transcribed, and viral particles are assembled forming new LASV progeny. Finally, 
the matrix Z protein associated with endosomal sorting complex required for protein 
transport are crucial for virion budding and release from the host cell151. 
Upon host infection, LASV targets tissues and organs starting with mucosa, intestine, 
lungs, urinary system and later the virus progresses into the vascular system150. Like 
filoviruses, LASV mainly targets cells of the immune system including antigen-pre-

















Figure 8: Schematic of Lassa virus life cycle. 
(1) LASV virus is attached to host membrane via its GP proteins (GP-1 and GP-2) and host 
membrane receptors (α-dystroglycan or TfR). (2) The virus enters the host cytoplasm by en-
docytosis in late endosome (LE). (3) Following its entry, a subsequent fusion mechanism oc-
curs with low pH. (4) Viral ribonucleoprotein (vRNP) is released and the genome is transcribed 
and replicated. (5) Newly translated viral particles are assembled to form new virion which is 
then transported to the membrane for budding. (6) Finally, new virus progeny is released from 











1.4.5 Lassa; Transmission 
The multimammate mouse also known as African rat has been identified as the res-
ervoir or host92. The first evidence of LASV in West African mouse specie, the M. 
natalensis, was demonstrated by Monath  et al in Sierra Leone in 1974152. LASV was 
isolated from mice sharing rooms with Lassa fever patients in an on-going LASV out-
break in Sierra Leone. Later, another investigation to indicated the possible similarity 
regarding LASV reservoir between M. natalensis in Sierra Leone compared to those 
in Nigeria was performed by Wulff et al. in 1975153. During the investigation, blood, 
tissues and urine from 8 different rodents’ species broadly collected in Nigeria in Be-
nue-plateau (North-eastern) were cultured in African green monkey kidney cell lines 
(Vero E6 cell) for LASV isolation. Of 151 rodents tested, the study reported LASV 
isolation from 8 wild rodents including M. natalensis (5), R. rattus (2) and M. minutoi-
des (1). Unfortunately, no virus was isolated from rodents’ urine. Recently, LASV was 
isolated from two new rodent species including H. pamfi (forest dwelling rat) and M. 
erythroleucus 154. Those rodents were collected in Nigeria and Guinea. Strains from 
Nigeria were sequenced using next generation sequencing (NGS) and strains from 
Guinea used Sanger sequencing154.  
Notably, rodents largely circulate in savannas and forests of African countries includ-
ing West, Central and East Africa. Multimammate rodents are found in occupied 
houses and are consumed in some places. Consequently, infected rodents (virus car-
riers) spread or shed the virus through urine and faeces for a long period of time and 
human-rodent contact is a source infection. So, human infection occurs when con-
suming contaminated food or infected rodent meat or when manipulating infected 
materials. Person-to-person transmission can occur from direct contact (blood, urine, 
excretion, tissue) of infected subjects or through indirect contact when manipulating 
contaminated materials (e.g. medical equipment or domestic materials)91,92,93. Also, a 
possible airborne transmission mode has been commented upon by Goeijenbier et al 
and Stephenson et al 101,155. The reports indicate that airborne transmission can occur 
through inhalation of infected tiny particles in air (aerosol). Healthcare workers are at 
high risk of exposure therefore protective equipment should be used prior to sample 
handling or when caring for infected patients. It is also reported that Lassa virus may 







Lassa virus transmission and spread in population 
 
Figure 9: Schematic of Lassa virus transmission.  
LASV circulates in host reservoir (M. natalensis) population and primary infection occurs from 
infected host to human through contact with infected fluids or materials (zoonotic transmis-
sion). Lassa virus infection disease spill over in community from human to human contact via 
infected bodily fluids and in several cases, Lassa fever disease is mild or asymptomatic and 













1.4.6 Lassa; Immune response 
LASV is an Old World Arenavirus which is responsible for haemorrhagic fever infec-
tion disease in Human and NHPs. Lassa fever disease occurs sporadically in some 
West African countries and is endemic in Nigeria with multiple reported outbreaks 
since the discovery of the virus156. The incubation period is about 21 days with non-
specific clinical manifestations. The major symptoms are common to that off other 
tropical diseases (malaria, typhoid fever and influenza) and include fever, fatigue, 
haemorrhaging, gastro-intestinal symptoms, respiratory and neurological symp-
toms157. 
Following LASV infection, the host immune system quickly responds first non-specif-
ically then specifically as the virus induces effective immunity. However, fatal outcome 
of the disease might be associated with defective immunity or immunodepression158. 
Notably, LASV first infected cells are dendritic cells (DCs), macrophages (MPs) and 
antigen presenting cells (APCs) in which the initial viral replication cycle occurs49. 
Following infection of APCs, the virus will spread to the mucosal tissues and skin, 
secondary lymphoid organs and liver, hepatocytes, fibroblasts and endothelial cells 
are targets for viral replication. Normally, DC and MP cells activate the innate immune 
response through the induction of inflammatory mediators and subsequently initiate 
adaptive and cellular response to control viral infection159. Conversely, LASV-infected 
DC cells do not produce inflammatory cytokines (crucial to induce adaptive immunity) 
nor express activation molecules at their surface160. In fact, LASV infection fails to 
maturate DCs, consequently, the absence of DC activation and maturation in LASV 
infection might be associated with the immunosuppression observed in severe infec-
tion. In addition, it is reported that LASV-MP infected cells are not activated which 
extremely favours viral spread as otherwise the activated MP increase viral clear-
ance161,162.   
Furthermore, the inhibition of innate immunity caused by LASV NP protein has been 
documented163,164. These experiments demonstrated that Arenaviruses’ NPs, except 
the Tacaride virus, inhibit the production of type I IFN, IRF3 activation and nuclear 
translocation in response to viral infection. These attributions depend on the presence 
of a dsRNA-specific to the 3’-5’ exonuclease in the C-terminal part of the viral pro-
tein163,164.  Flatz et al demonstrated a two-faced role for T cell responses encountered 
in LASV infection165. Both normal laboratory mice and genetically engineered mice 
(HHD mice) with a humanized repertoire of T cells were used as animal models. While 
inoculated with live LASV, normal laboratory mice show resistance to the virus while 
HHD mice succumbed. Furthermore, HHD mice, containing humanised T cells that 
were experimentally removed could resist LASV infection. The study reported that 
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HHD mice with T cell depletion survived LASV infection whereas, HHD mice with no 
T cell depletion succumbed LASV infection. It established that the absence of exten-
sive monocyte/macrophage activation in T cell-depleted mice contribute to deleteri-
ous innate inflammatory reaction. Finally, the study concluded that host immune de-
fences against LASV either defeat the virus or act as essential facilitator for disease 
maintenance and evolution165.  
Specific immune response in LASV infection is mediated through early IgM antibody 
production. However, Johnson et al. measured the level of LASV antibodies in hospi-
talized patients and found that LASV disease outcome was associated with viremia 
but not with the development of antibodies166. Alternatively, the study reported that 
death possibly occurs before the usual time of IgG antibody production.  
 
1.4.7 Lassa; Clinical symptoms and treatment 
The incubation period for LASV is about 21 days91. In about 80% of people, Lassa 
fever is mild or asymptomatic and is left generally undiagnosed99. Mild symptoms are 
usually fever, tiredness, weakness and headache. However, in about 20%, Lassa 
fever symptoms can be severe including; respiratory distress, chest pain, abdominal 
pain, vomiting and bleeding (gums, eyes, nose)94. Death generally occurs 10-14 days 
post onset of disease and is associated with multiple organ failure. In some cases, 
neurological problems have been notified as palpitation, loss of hearing and enceph-
alitis131. Despite LASV infection prevalence in most African countries, it is reported 
that only 1% of Lassa fever infections result in death156.  Although, the mortality rate 
in patients hospitalized from Lassa fever infection disease is reported to be approxi-
matively 15-20%167.  Additionally, foetal death, miscarriage and, long term complica-
tions which result in deafness have been described in some cases157,168. Due to the 
number of febrile illnesses (e.g. malaria, typhoid fever), LASV disease often goes 
undiagnosed. To date, a wide range of laboratory tests are available for Lassa fever 
infection disease detection. These tests include RT-PCR169, ELISA and plaque neu-
tralization assays, immunofluorescence and cell culture 170.  
For decades, Lassa fever has been successfully treated with Ribavirin an antiviral 
drug. It is reported that the main action of ribavirin is to prevent host cells from dying 
in reducing the inflammatory response171. However, various mode of action of ribavi-
rin have been evaluated such as direct inhibition of viral RNA-dependent RNA poly-
merases and host inosine monophosphate dehydrogenase, modulation of the host 
immune response, inhibition of viral capping enzymes and lethal mutagenesis171,172. 
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Nowadays, both favipiravir and  ribavirin have been under preclinical trials and favipi-
ravir has been indicated as the best therapeutic approach in LASV infection dis-
eases173. Nevertheless, early diagnose, effective supportive care and detecting asso-
ciated co-infections contribute to patient recovery. There is no approved treatment for 
LASV infection: however, human monoclonal antibodies have been recently experi-
mented in Guinea pigs and NHPs models174,175. Reports established that when the 
treatment is initiated at advanced stages of the disease, there was a possibility to 
rescue 100% of NHPs challenged with live LASV. 
To date, there is no available licensed vaccine for Lassa hemorrhagic fever. However, 
multiple vaccine candidates in development are showing efficacy in animal models at 
the preclinical trial stage. Those vaccine candidates are non-replication component 
vaccines such as alphavirus replicons, whole inactivated LASV and DNA vac-
cines176,177,178. There are multiple animal models for vaccine experimentations, such 
as Guinea pig, mice, cynomolgus monkeys, macaques; however, NHPs are indicated 
as the gold standard presenting numerous conditions similar to that of humans173,179. 
It follows that the selection of animal model is related to the ability of inducing strong 
cell-mediated cross-protective immunity against different LASV lineages.  
To conclude, LASV disease requires deep investigation (i) to elucidate the pathogenic 
mechanisms leading to disease fatal outcome and (ii) to understand the potential 
cause of LASV asymptomatic infection shown in some countries as Guinea despite 




1.5 Study aim and objectives 
The primary purpose of this study is to assess the level of sub symptomatic EBOV 
infection in communities at high risk of exposure in the forested region of Guinea. 
Those exposed people within the community are mainly bushmeat hunters and their 
household family members, located in remote places, close to the nature and deep 
within the forest.  Volunteer recruitment was conducted in year 2017 and a total of 
517 serum samples were collected and thoroughly assayed on ELISA (using simul-
taneously Casein and ChonBlock blocking buffers), Western blot analysis and flow 
cytometry test for EBOV GP antibodies detection. Alternatively, an ELISA assay was 
performed for LASV NP detection. Our study intends to (i) demonstrate the circulation 
of EBOV in the forested region of Guinea prior to the 2013-2016 EVD outbreak in 
Guinea; (ii) assess the degree of sub symptomatic, mild or unrecognized EBOV in-
fection disease in the Macenta prefecture, (iii) asses the incidence of LASV infection 
in Macenta prefecture and, (iv) help to understand and identify practices that promote 
the circulation and transmission of zoonotic pathogens.  
Regarding the growing importance of zoonosis and their impact on public health, sur-
veillance of emerging diseases is essential to avoid serious epidemic outbreaks in 
communities. This study will help to understand and probably prevent the risk of con-
tamination and disease spill over via community behaviour with regards to bushmeat 
hunting, manipulation and consumption. 
Finally, this seroprevalence study attempts to develop and strengthen Guinean ca-
pacities for scientific research. The existing network between European and African 
researchers of this study is based on more than a decade of collaborative projects in 
Africa led by Professor Günther of Bernard Nocht Institute of Tropical Medicine 
(BNITM) and supported by a grant from food and drug administration program (FDA) 
of the United States awarded to Professor Miles Carroll of Public Health England 













































2.1 Sample collection   
Human peripheral blood samples were collected every week at the nearest available 
health centre. Sampling sites were selected based on available facilities, travelling 
distance for volunteers and accessibility by motorbike. A small volume of blood (ap-
prox. 5 ml) was collected into BD vacutainer® blood collection tubes (red cap. REF: 
367895) by experienced, local, phlebotomists. Volunteers were compensated for their 
loss of time and any inconveniences experienced during sample collection according 
to Guinean ethics scales.   
Blood was collected into 5 ml of vacutainer blood collection tubes. These tubes con-
tained no anticoagulant and therefore blood could clot within two hours at room tem-
perature. Samples were transported to the field laboratory in a cool box at 4 ºC. In the 
lab, samples were centrifuged at 2,000 x g for 10 minutes at room temperature. Se-
rum was then aliquoted into 2 ml microtube RT-PCR tubes (Starsted, REF 
72.694.406) in an air purifying class II microbiological safety cabinet (Envair Ltd, Eng-
land). Serum aliquots were labelled and stored at -20°C and later shipped on dry ice 
by an International Airline Transport Association-compliant safety shipper (World 
Courier) to the United Kingdom. Finally, samples were processed at PHE Porton 
Down laboratories and at University of Marburg.   
This study was ethically approved by the board of UK research ethics council as well 
as the national research for health ethic committee of Guinea (permit 
Nº012/CENRS/2017; Appendix 1). 
 
2.2 Enzyme-Linked Immunosorbent Assays (ELISA) 
Enzyme Linked Immunosorbent Assays (ELISA) were used to measure EBOV- and 
LASV-specific antibodies in serum samples.  
 
2.2.1 Indirect ELISA assay procedure 
Indirect ELISA detects an analyte by way of using a secondary antibody. The specific 
antigen of interest is immobilized (coated) onto an appropriate ELISA plate. Then 
primary antibody (usually patient specimen) is added to the plate. The secondary an-
tibody (enzyme-conjugated) is added and specifically binds to the preformed complex 
antigen-antibody on the plate. Finally, chemical substrate is added which initiates a 
colour change that is read at various optical densities by an ELISA plate reader ( 
Figure 10). Indirect ELISA is more sensitive than other platform as the secondary an-
tibody can amplify the signal190.  
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ELISA assay procedure for EBOV GP antibody detection 


















Figure 10: Description of ELISA assay procedure (Indirect ELISA) 
A)Detection of Anti-EBOV GP antibody in human blood sample using Goat anti-human IgG 
alkaline phosphatase conjugated in the presence of p-NPP substrate. (1) EBOV GP tetramer 
antigen is coated into ELISA NUNC high binding plate. (2) Volunteer’s serum, probably carry-
ing anti-EBOV antibody (primary antibody) is added to the plate which may bind to the EBOV 
GP antigen coated. (3) Goat anti-human IgG (secondary antibody) conjugated with alkaline 
phosphatase is added and binds to the primary antibody. (4) P-NPP substrate is added and 
interact with the enzyme giving colour change into the plate. (5) Yellow signal equates to pos-
itive and indicates the possible exposure to EBOV. However, this should be measured on 
ELISA reader and subsequent OD value is analysed and compared to controls for validation. 
 
This figure used images that were created with Biorender.com and are permissible to use. 
B. ELISA plate showing response to EBOV GP 
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2.2.2 Ebola virus Glycoprotein detection 
Using participant serum samples, the detection of antibodies specific to EBOV (Ma-
kona) GP was achieved by coating Nunc high binding plate-Sigma 96-well plates 
(Sigma, Lot. Number M9410-1CS) with 50 µl of recombinant protein at a final con-
centration of 1 µg/ml, diluted in Phosphate Buffered Saline (PBS) (PHE media. Lot 
number 1755496). The EBOV GP was purchased from the Jenner Institute at Oxford 
University and is a trimerized Zaire strain (amino acids 1-649, GenBank protein 
AHX24649.1). The protein contains a c-tag EPEA (glutamic acid-proline-glutamic 
acid-alanine) and was expressed in HEK293E cells. Cell culture supernatant was har-
vested presumably four days after transfection and concentrated using a Pellicon 3 
Tangential flow filtration system (Millipore, Herts, UK). Protein purification was 
achieved using an AKTA pure system (GE Healthcare, Bucks, UK) with a C-tag affin-
ity capture set up (Thermo Fisher Scientific, UK) along with a polishing size exclusion 
chromatography (SEC), using a SepFast GF-HS-L 26/1000 column (Biotolomics, 
Durham, UK). SEC peak fractions corresponding to the trimeric EBOV GP were 
pooled and the molecular weight further confirmed by blue native PAGE (Thermo 
fisher scientific, UK). The purified protein was quantified by spectrophotometry 
(Nanodrop. Thermo Fisher) aliquoted and stored at -80˚C until use.  
Coated ELISA plates were incubated overnight, in the fridge, at 4 ˚C. The following 
day plates were washed six times in PBS/0.005% tween (PHE media. Lot number 
P7949) using the AquaMax 4000 with 96-well plate wash head (Molecular Devices). 
Plates were then blocked using 200 µl of casein (Thermo Scientific. Lot number 
37528) or ChonBlock (Chondrex. Inc. Redmond. WA. Cat. Number 9068) and incu-
bated at room temperature for one hour to block any nonspecific active sites. While 
this was occurring, samples were prepared in 96-well “Dummy” plates (Nunc low bind-
ing plates. Cat. Number 611F96) as illustrated in Figure 11. Samples were diluted 
either 1:100 or 1:500 using either casein or ChonBlock. To quantify results in interna-
tional units per millilitre (IU/ml) a standard curve was used. This curve contained 
pooled plasma from three EVD survivors of the 2013-2016 West Africa outbreak and 
was quantified in house against the WHO international standard 15/262 180. Addition-
ally, to map the consistency of results, an internal QC which consisted, again of three 
pooled EVD survivor plasma samples was acquired on every plate at a dilution of 
1:500. Finally, negative plasma from non-infected West African nationals was also 
acquired on every plate.  
Following incubation with either casein or ChonBlock ELISA plates were washed six 
times and 50 µl of sample transferred from the “Dummy” plate to the test plate. Sam-
ples were then incubated for a further two hours at room temperature. Secondary 
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Goat anti-human Fc, alkaline phosphatase (AP) conjugated (Cat. Number A3187, 
Sigma) antibody was prepared at a dilution of 1:1000 in either casein or ChonBlock. 
Following their incubation, plates containing test sample were washed six times and 
50 µl diluted secondary antibody was added to each well. Samples were incubated 
for one hour at room temperature and while this was occurring the developmental 
substrate was made by mixing one 4-Nitrophenyl Phosphate, 20 mg (Cat. Number 
N2765. Sigma) into 16 ml of distilled water and then adding 4 ml of 5X diethanolamine 
(Cat. Number 34064. Pierce) to give a 1x solution. Substrate buffer was kept at room 
temperature in the dark until use. Samples were finally washed a further six times 
before adding 100 µl of substrate buffer. Samples were left to develop in the dark for 
20 minutes before being analysed on a SpectraMax M3 spectrophotometer (Molecu-
lar Devices) with Softmax™7.0 software program. Plates were read at 405 nm and 
data was exported in excel format before being graphed in either Excel (Microsoft) or 
GraphPad™ V8 software. 
 
 
Figure 11: Representation of ELISA plate layout.  
In total 16 samples were assayed per plate including controls. NEG, Blank and samples were 
duplicated each respectively 1/100 and 1/500 (e.g. A3/A4 and B3/B4 for NEG; A5/A6 and 
B5/B6 for sample 1). (2) QC was duplicated respectively as 1/400 (top rows: A1/A2) and 1/800 
(bottom rows: B1/B2). (3) Standard was serially diluted 10 times staring 1/100, 1/200, 1/400 






2.2.3 Lassa virus IgG detection 
This assay was performed using the BLACKBOX® LASV IgG kit from BNITM. The Kit 
was used as per the manufacturer’s instructions. In addition to negative and positive 
controls, blank and background controls were added in order to monitor non-specific 
binding of proteins to reagent contaminants or to the ELISA plate. The BLACKBOX® 
LASV IgG ELISA kit is designed for qualitative serological detection of acute or past 
LASV infection using conjugate IgG (biotinylated recombinant LASV antigen). 
All reagents were at room temperature for 20 minutes before use. Frozen samples 
were thawed and vortexed prior to processing. Samples, as well as positive and neg-
ative controls were diluted 1:50 in sample dilution buffer. Pre-coated LASV IgG micro 
well plates were removed from the alumina pouch and were manually washed three 
times with 300 µl of washing buffer after which 25 µl of IgG LASV antigen (conjugate 
IgG biotinylated recombinant LASV antigen) was added to each well. Additionally, 25 
µl of pre-diluted sample was added to each well as shown on the plate layout (Figure 
12).  
Samples were incubated for 24h at 2 – 8 ºC in a wet chamber, this was made with 
wet paper towels inserted into a small closing box. This keeps the micro well plates 
from drying and prevents IgG LASV antigen and antibodies denaturation. Following 
this incubation plates were washed five times with 400 µl of washing buffer before 
adding 50 µl of diluted HRP-streptavidin at a final concentration of a 1 µl/10 ml in 
conjugate dilution buffer into wells. Plates were covered with adhesive plastic and 
incubate for one hour at 2-8 ºC. Following this incubation period, plates were washed 
three times as described above and 100 µl of substrate 3,3′,5,5′-Tetramethylbenzi-
dine (TMB) was added to each wells. Plates were incubated for 10 minutes in the 
dark at room temperature. Finally, stop solution was added (100 µl) before being an-
alysed on a ‘SpectraMax M3 spectrophotometer (Molecular Devices) using Soft 






Figure 12: Representation of ELISA plate layout for LASV IgG detection.  
In total 89 samples were assayed per plate with four controls. NEG, Blank (BL) and back-
ground (BG) were duplicated. NEG and positive controls were provided with the kit. Blank and 
background noises controls were added on the bench to monitor, non-specific bindings of 




2.2.4 Lassa virus IgG detection ELISA assay procedure. 
To evaluate anti-LASV IgG in our samples, we performed ELISA technique. The 
Blackbox LASV IgG ELISA kit is provided with a plate coated with an undisclosed 
protein that binds immune complexes (LASV antigen and anti-LASV IgG). The kit 
includes positive and negative controls. In addition, two controls blank and back-
ground noises were added to monitor non-specific bindings. In the blank wells, no 
serum was added in order to measure detection antibody (secondary antibody) inter-
action with ELISA plate plastic surface. Although, background wells were LASV anti-
gen free so that to measure specimen wild proteins binding to ELISA plate. Further, 
test serum is incubated with LASV protein to form immune complex. Then sample is 
incubated with ELISA plate. Afterward, subsequent protein labelled with enzyme (e.g. 
streptavidin-HRP) is added to the plate and binds to a biotinylated site of the LASV 
protein. Finally, the reaction is visualized when applying substrate and stop solution 





























Figure 13: Competitive ELISA assay for LASV detection.  
A) (1) ELISA plate is provided with capture molecule that binds immune complexes.  (2) Par-
ticipant serum (anti-LASV IgG) and LASV antigen (Biotinylated) are incubated in vitro to form 
immune complex (antibody-antigen) which is then added to the ELISA plate. (3) Streptavidin-
HRP labelled is added and binds to the immune complex. (4) Stop solution and substrate are 
simultaneously added for antibody detection. (5) Yellow signal equates assay positivity. B) 
Schematic representation of performed ELISA plate for the detection of anti-LASV IgG anti-
body. Four controls are used including NEG and POS provided with the kit; Background (BG) 
and blank (BL) are controls made on bench. BG wells are with no LASV antigen addition to 
monitor serum proteins binding to ELISA plate surface and BL wells are with no anti-LASV 
IgG (serum) addition to monitor LASV antigen interaction with ELISA plate surface.  Yellow 
signals indicate sample positivity.  
 
This figure used images that were created with Biorender.com and are permissible to use. 
B. ELISA plate showing Lassa positives 
A. ELISA procedures  
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2.3 Ebola virus protein detection by western blot 
EBOV proteins including GP (Oxford university. In house), NP (Gentaur. REF. 
MBS1206629) and VP40 were diluted in Laemmli lysis buffer (Sodium lauryl sarco-
sine. Cat. Number: 38733. Sigma). Mixtures were then heated at 95 ºC for 10 minutes 
to denature proteins. Denatured samples (10 µl) were then loaded onto 4-12 % So-
dium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (REF: 
NW04122BOX. Lot: 19022611. Life technology). Protein standard-Magic Mark XP 
(Lot: Lc5602. Thermo Fisher) and Protein standard Pre-stained (Lot: 10640504. 
Thermo Fisher) ladders were used. Both proteins are thawed, gently vortexed, mixed 
at equal volume and 10 µl is loaded into the SDS-PAGE gel. Gel electrophoresis was 
run using XCell sureLockTM chambers (Invitrogen) using MOPS-SDS (REF: NP0001. 
Lot: 1935953. Thermo Fisher) with the addition of an antioxidant (N, N-dimethyl form 
amide, sodium bisulfite) (REF:NP0005. Lot: 1909040. Thermo Fisher) as a running 
buffer. Samples were run using a power pacTM Bio-RAD machine at 200 volts for 50 
minutes.   
Following separation by electrophoresis, proteins were transferred from the gel to 
polyvinylidene (PVDF. Cat. Number: LC2002. Invitrogen) membrane using iBlot 
transfer stack (REF: IB401001. Lot: 120319-01. Thermo Fisher) and iBlot machine 
(iBlotTM. CEPR portable. Lot: 52701. Invitrogen). Following protein transfer, the PVDF 
membrane was blocked for two hours in a 15 ml tube on a roller (HR-120. Max 120g, 
Mini10 mg. REF 1370045) in 5 % non-fat milk (REF: A0830.0500. VWR), subse-
quently, the samples were stored overnight at 4˚C. 
The following day PVDF membranes were washed five times with 0.05 % PBS 
Tween-20 solution. Then, membranes were incubated with 2.5 ml test serum sample 
at 1:100 in non-fat milk or EBOV specific antibodies as rabbit anti-EBOV GP 100 μl 
(REF: 0301-012. Gentaur); rabbit anti-EBOV NP 100 μl (REF: 0301-015. Gentaur) 
and rabbit anti-EBOV VP40 100 μl (REF: 0301-010. Gentaur). Samples were incu-
bated for 2 hours at room temperature on a rolling platform, after which, they were 
washed five times and incubated with 1:1000 secondary anti human or rabbit IgG-
HRP (REF: A2290-1ML. Sigma). Samples were again incubated 1-2 hours before 
being washed a final time and developed using enhanced chemiluminescence (ECL) 
prime western blotting system (REF: RPN2232. Sigma) solution. PVDF membranes 
were developed by adding 2.5 ml of equivalent volume of ECL solution A and B and 
incubating membranes for 30 second in dark place before reading the membranes on 
a ChemiDocTM XRS+ imaging system (Bio-Rad). Images were obtained every 30 sec-
onds over a five minutes period and selected images were transformed and saved as 
TIFF files.   
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Figure 14: Western blot assay description.  
(1) Separation of EBOV GP, NP and VP40 proteins on SDS-PAGE gel electrophoreses. (2) 
Protein transferred from the gel to PVDF membrane. (3) Protein detection using primary hu-
man antibodies and goat anti-human IgG-HRP, visualized by ECL (sigma). (4) Protein band 







2.4 Anti-EBOV IgG subclass detection 
This assay aimed to determine the contribution of various IgG isotypes to any deter-
mined EBOV antibody response. First, EBOV protein (Zaire GP tetramer. Oxford) was 
conjugated to the surface of carboxyl beads (Lot: CMPAK-4068-6K. Spherotech). 
These beads (107/ml) are magnetic and come as a set of six peaks, with each peak 
having a distinct intensity of APC fluorescence. Beads were initially sonicated for 20 
seconds and removal of supernatant achieved using a magnetic stand (Easy Eights™ 
EasySep™ Magnet. Stemcell technologies. Lot: 18103).  Beads were then washed 
twice using in house washing buffer (PBS, 0.1 % BSA and 0.5 % Triton X100). and 
200 µl of activation buffer was added. Activation buffer consisted of monobasic so-
dium phosphate (MSP) (Lot: 10751135. Fisher Scientific) with dibasic sodium phos-
phate (DSP) (Lot: S0876-100G. Scientific Laboratory Supply); N-hydroxysulfosuccin-
imide (Sulfo-NHS) to 6.25 mg/ml (Lot: 24510. Life Technology) and 1-ethyl-3-[3-di-
methlyaminopropyl] carbodiimide-HCl (EDC) to 6.25 mg/ml (Lot: 22980. Life Technol-
ogies). 
Samples were incubated for 20 minutes and then washed three time with MES buffer. 
Next, beads were incubated with either 40 µl of EBOV GP (EBOV tetramer 
0.35mg/ml. Oxford); 40 µl of recombinant EBOV NP, partial mammalian cell derived 
(0.15 mg/ml; 0.35 ml. Lot: G251468. Gentaur); 40 µl of VP40 (REF: 0301-010. Gen-
taur) and 200 µl of MES. Samples were incubated for 2h in the dark at room temper-
ature on a rotating mixer (Lot: 130-090-753. MACS, Miltenyi Biotech).  Following the 
incubation period, beads were washed twice with blocking buffer (PBS, 0.1 % BSA, 
0.05 % Sodium Azide and 0.02 % Tween) and re-suspended in storage buffer (PBS, 
0.1 % BSA and 0.05 % sodium Azide). Samples were then stable for up to six months 
at 4˚C. 
For IgG isotype detection all reagents were at room temperature before use. Beads 
(20 beads/ µl), conjugated to the EBOV protein of choice were diluted into assay 
buffer (1xPBS and 0.1% bovine serum albumin) to obtain approximatively 1000 beads 
per tube. 10 µl of test serum (volunteers’ samples) was then added to 100 µl of pre-
pared conjugated beads. Samples were incubated for one hour at room temperature 
in the dark on a rotating mixer. Beads were then washed once with assay buffer and 
100 µl of diluted secondary antibody (human IgG1 Isotype control recombinant anti-
body; 1.0 µg/ml. Lot:403504. Bio legend) was added. Samples were incubated for 
one hour at room temperature on the rotating mixer. Finally, beads were washed twice 
with assay wash, re-suspend in storage buffer and analyzed on a BD Acuri™ C6 plus 
flow cytometer (BD Biosciences). Following acquisition, samples were analyzed using 
FlowJo™ V10 (Becton, Dickinson) and GraphPad V8 software. 
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Figure 15: Multiplex beads assay description.  
Antigen binds to Luminex beads in vitro.  Human serum possibly carrying anti-EBOV antibody 
(primary antibody) is added and the antibody binds to the antigen (EBOV GP) coated on the 
beads. Finally, Anti-human IgG-PE (detection antibody) biotinylated is added and binds to the 
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3.1 Study framework 
This sero-prevalence study was carried out in the Republic of Guinea, Western Africa 
(southwest, midway between the equator and the Tropic of Cancer, Lat: 9.749615°. 
Long: -13.456806°). The country covers an area of 245,857 km2 and is composed of 
both plains and mountains reaching in some places to an altitude of over 1500 m. It 
is bordered by the Atlantic Ocean, Sierra Leone, Liberia, Côte d'Ivoire, Mali, Senegal 
and Guinea Bissau181. With regards to the diversity of ecological conditions, Guinea 
is divided in to four regions including lower Guinea, middle Guinea, upper Guinea and 
Forested Guinea. To date, it is reported that the country features 260 vertebrate mam-
mals species, 518 birds species, 140 reptiles species and 31 viruses discovered181. 
This study targeted groups of people living in remote villages, close to nature, deep 
in the forest and near large rivers. We intend to investigate the circulation of EBOV in 
the local population prior to the 2013-2016 EVD outbreak in Guinea and therefore we 
focused on remote villages that had never previously reported case of EVD. Our co-
hort primarily includes bush meat hunters, their household family members and peo-
ple involved in both bushmeat manipulation and consumption. This population is 
known to be at high risk of exposure to viruses that coexist with forest animals (zoon-
otic diseases). We performed serological testing on human samples to determine the 
presence of anti-EBOV antibodies. Immunity to LASV was also studied as both Ebola 
and Lassa viruses are responsible for severe haemorrhagic fever in humans and 
NHPs.  
Our study focused on the region of Macenta (Figure 16) which has a young and un-
educated population with an approximative age of 35. In this area, population main 
occupations are farming and hunting. Bushmeat consumption results in daily contact 
with wildlife either through trapping, hunting or butchering and these are thought to 
be the major routes of viral transmission. This study attempts to contribute to the 
development of the Country’s early awareness system for emerging disease contain-
ment. It is part of the One Health approach for disease surveillance, prevention, con-
trol and eradication established in country after the 2013-2016 EBOV outbreak182. 
The One Health approach is an interdisciplinary and multi-sectoral framework includ-
ing the Ministry of Health, the Ministry of Agriculture, Livestock and Fisheries. This 
multi-sectoral collaboration highlights the public health importance of endemic and 
epidemic zoonoses management. It provides capacity building programs, disease 
surveillance, workforce development, research, coordination and investigation of an 
outbreak response. Its implementation considers actors and communities concerns 
to assess the risks of human exposure to filoviruses in order to prevent and control 
emerging and re-emerging viral diseases within the population. Results from the study 
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can be used to strengthen the national security agency system for disease surveil-
lance (ANSS) and that of other West African countries in general. 
This chapter describes volunteer and study area selection. It also indicates population 






Figure 16: Representation of Macenta prefecture map  
Map of the Republic of Guinea. It comprises 7 administrative regions including Kindia (Ki), 
Boke (Bo), Labe (La), Mamou (Ma), Faranah (Fa), Kankan (Ka) and N’zerekore (N’Ze). Red 
colour indicates the forested region of Guinea with Nzerekore as the regional capital city. Yel-












Wildlife Protection Code and Hunting Regulations have been in place since February 
1990 by ordinance Nº007/PRG/SGG/90 and reviewed on December 1997 under law 
L/97/038/AN181. Although the code defines hunting areas these are often violated, 
and poachers are taken to the law court of the prefecture. In 2013, the national office 
of water and forest management censured 2,990 gun-hunters in Macenta prefecture. 
Approximatively 31 viruses were discovered and classified in Guinea over more than 
a decade181. Recently, Piet et al. discovered a novel arterivirus in African giants Shrew 
(Olivier’s Shrew virus 1, A) in Meliandou village at Gueckedou183. Additionally, the 
country’s biodiversity is almost identical from one region to another with minor differ-
ences in seasonal period. In general, all kinds of animal species including vertebrate 
mammals, birds and reptiles are subject to hunting and consumption without distinc-
tion.   
 
3.3 Study zone selection 
The forested region of Guinea was selected for this study due to the fact that the West 
African outbreak of 2013-2014 originated within the region59. Also, the region com-
pared to others, encounters greater diversity of wildlife (fauna) which may be reser-
voirs for several types of viruses including filoviruses and Arenaviruses. Population 
occupations such as farming, and hunting constitute the main route of exposure to 
zoonotic infection in the zone likened to other regions in Guinea with less exposure 
to wildlife. 
Our study zone Macenta prefecture is in the forested region of Guinea and covers an 
area of 7046 km2 with an estimated population of 278,456 inhabitants (Table 4)97. It 
comprises 15 sub-prefectures and 314 villages with an approximative density of 41 
inhabitants per km2. The residential population in the urban and rural areas are ap-
proximately 65,755 and 212,701 inhabitants respectively.  Macenta is characterized 
by a significant rain forest with an abundant hydrographic network made up of rivers, 
flows and streams (e.g. Makona, Loffa, Diani). Its biodiversity is almost identical from 
one side to another but differs slightly from other regions. The general population of 
Macenta is young with the average age ranged between 25 to 45 years and life ex-
pectancy at around 55 years for men and 65 years for women97.  
Within the Macenta region we were able to work with a number of sub-prefectures to 




Table 4: Population of Macenta prefecture. 
Macenta is composed of 14 sub-prefectures, 314 villages and Macenta town centre. A sub-
prefecture may count more than 50 villages. In total, 7 sub-prefectures were selected for the 
study. An approximate number for the population (male and female) from each sub-prefecture 
including its surrounding villages as for 2014 census can be seen97. 
Prefecture Male Female Total 
Balizia 7101 7591 14692 
Binikala* 8574 9113 17687 
Bofossou* 6600 7203 13803 
Daro 6969 7576 14545 
Fassankoni* 6415 7477 13892 
Kouankan 14500 15725 30225 
Koyama* 11623 13389 25012 
Macenta centre** 32014 33741 65755 
Zebela 7842 8426 16268 
Oremai* 4261 4741 9002 
Panziazou 3933 4507 8440 
Semgbedou 6510 7254 13764 
Seredou* 9651 10598 20249 
Vasseredou 4114 4489 8603 
Watanka* 2938 3581 6519 
Total 133045 145411 278456 
            * Study areas         





3.3.1 Study villages selection 
The selection of villages for this study was based primarily on their location and their 
exposure to EVD during the 2013-2016 outbreak (Figure 17). Selected villages were 
close to nature, deep in the forest and near large rivers. This was so we could involve 
people at high risk of exposure to zoonotic disease as their daily activities involved 
contact with wildlife through subsistence activities such as farming and hunting. Some 
villages on the main national road were included as they constitute the main route of 
disease spread from remote places to agglomerate cities. An established trade oc-
curs once a week in those villages where sellers and buyers meet and exchange 
products as fruits and meat (fresh or smoked). Although, some of the villages were 




Myself, a Guinean national, originates from Macenta prefecture which is occupied by 
the Toma tribe. This made interactions with the local people possible and was instru-
mental in our ability to set up cohorts within these rural villages. Although, the pres-
ence of ethics approval document (Annex 1) signed at the back by the highest ad-
ministrative authorities such as the governor of Nzerekore and the prefect of Macenta 
enhanced population certainty about the study. However, minor resistances were 
raised mainly with regard to the past EVD and its consequences in the zone.   
        
Map to locate sample collection villages 
 
Figure 17: Representation of the sample collection sites  
Map showing the location and whether the village had previously experienced EVD. Of 314 
villages in Macenta, 44 participated to the study amongst which 16 villages, red dots, reported 
EVD case (affected) and 28 villages, green dots, reported no EVD case (unaffected) during 
the 2013-2016 outbreak. Dots sizes are related to the number of samples collected in each 








3.3.2 Volunteers recruitment  
Volunteers were recruited upon agreement. First, administrative authorities in the vil-
lage were notified about the study and mass sensitization was organised to communi-
cate the project. Participants were then selected with the support of both the chief of 
the village and the chief of hunters. Regarding the number of samples to be collected 
for the study (primarily 400), the number of participants per village was limited in order 
to cover a large area of the study zone. Notably, villages are divided into families 
which may count up to 7 in some places. Families are divided into households and at 
least two households were selected per family within the village. Furthermore, an in-
dividual interview was organised for participants and details were assembled using a 
data collection sheet (Questionnaire, Appendix 2). Volunteers under 16 of age, preg-
nant women, travellers and/or visitors, and those suffering from chronic diseases 
were excluded. Finally, consent forms were signed prior to sample collection (Appen-
dix 3).  
The study participants were empirically classified in to three age groups including 
young (16-24), adult (25-55) and elderly (>55) (Table 5). Both males and females 
were involved and volunteers under 15 of age were excluded for ethical considera-
tions. High participation rate was seen in the middle age group ranging between 25 
to 55 (n=374). This group is the most involved in farming and hunting activities. Also, 
it is composed of vigorous and healthy people and encounters high number of people 
within the population as the life expectancy is at 55 years old. In contrast, less partic-
ipation was seen in the old age group. This might be related to the exclusion of several 
participants with chronic diseases and the lower numbers of elderly people found in 
villages due to the early death of men.  
 
Table 5: Breakdown of study cohort with regards to age and sex.  
Three age groups were considered and both male and female participated. Volunteers under 
16 of age were not eligible. The adult age group (25-55) shows high participation rate while 
the old age group shows less participation. 
Age group Male Female Total 
16 – 24 30 56 86 
25 – 55 211 163 374 
>55 51 6 57 




3.3.2.1 Occupation of volunteers 
Within the villages, farming (agriculture) remains the primary occupation. However, 
people are involved in other activities such as carpentry, masonry, blacksmith, mer-
chant (small shop and bushmeat traders) and healthcare worker (alternative and 
modern medicine practitioners). Hunting is not considered as a professional activity 
but rather as a subsistence activity which is authorised for people aged over 20 
years184.  Our study not only considered hunters and close contacts but also volun-
teers practising other activities and involved in bushmeat manipulation and consump-
tion. Healthcare workers were included due to their involvement in caring for people 
presenting with any infectious disease.  
 
Table 6: Occupational data for study cohort participants.  
Hunters are found only amongst the male group. Household family members include wives, 
children, grand-parents and other relatives. Traders mainly include women and the workman 
group which is composed of young males. 
Occupation Male Female 
Hunters 242 0 
Household member  29 211 
Healthcare worker 23 11 
Workman 26 0 
Traders 1 15 
 
 
3.3.3 Participant outreach 
Volunteer recruitment and sample collection was conducted within 11 months inclu-
sively from February to December 2017. Out of 314 villages in Macenta prefecture, 
47 (14.96%) villages were contacted and 44 participated in the study. Villagers were 
informed about the study through mass communication and volunteers were individ-
ually interviewed for their consent. Though the study was largely accepted we did 
encounter minor resistances in some places which seemed to be related to the past 
EVD outbreak fear and trauma. It followed that due to fear, three villages refused to 
participate in the study. Entirely, women from another selected village didn’t show up 
for sample collection, likely due to pre-existing fears surrounding the context of the 
study. As a result, amongst 47 villages contacted, participants from 44 villages agreed 
to the study (Figure 18).   
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Samples were collected in sixteen villages known to have had previous exposure to 
EVD (affected villages) and in twenty-eight villages with no previous reports of EVD 
exposure (unaffected villages), as reported in the national database regarding the 
2013-2016 EVD management in Guinea97. This detailed data set is available in the 
Macenta Prefectural Health Direction (DPS) office. As the 2013-16 EVD outbreak 
progressed in Guinea, national health authorities were notified of any suspected 
cases in villages by healthcare agents broadly distributed and provided with mobile 
phones and motorbikes. Suspected people were then transported to the nearest ETC 
for EVD confirmation via RT-PCR testing. Data about EBOV presence in villages are 
available at the DPS in Guinea but unfortunately not published. We were able to visit 
such data sets at Macenta DPS to classify our selected villages as either affected or 
non-affected. More importantly, healthcare agents in those villages were involved in 
our study and mostly helped to confirm the accuracy of the data we collected from 
the DPS. In addition, Macenta population is about 300,000 habitants and the 44 vil-
lages selected for our study encounter approximatively 106,164 habitants which rep-
resent 38.52% of the general population of Macenta.  
The highest participation rate was seen amongst the 25-55 year olds with (374 of 
517), followed by 16-24 years old. Within the sample collection period, 212 house-
holds of bushmeat hunters were reached. Subsequently, with regards to community 
social life in the zone, each hunter possesses at least two wives, 5 children and two 
close relatives per household. So, we are confident that we have reached ~ 2,120 
people (≈10 peoples per household). This indicates how many people are at risk and 
how fast viral infection could spread when first contamination spillover event oc-
curs185.  
During both mass communication and interview stages, a number of questions were 
raised. Community as well as volunteers were eager; 1) to know what the benefit of 
the study for volunteers and the entire village in the future would be, (2) to understand 
why samples were collected from healthy peoples instead of diseased peoples, (3) to 
be notified of any other disease and provide medication in the event of samples being 
found positive. In response to these questions, we were able to explain how risky the 
population is with regards to zoonotic disease exposure through their daily activities. 
Mainly, these activities are bushmeat hunting, manipulation and consumption. Im-
portantly, we emphasised on the fact that wildlife carrion found in the bush should be 
avoided for consumption as no one knows what they died off. This constitutes the 
riskiest exposure to viral transmission and spread. We also explained how possibly a 
disease could spill over in the entire community (village) through only one first expo-
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sure (index case). Further, we highlighted the fact that the study would help to under-
stand virus circulation in the zone and possibly prevent future outbreak occurrence. 
Finally, we suggested that in the event of any outbreak occurrence, there may be a 
possible shipment of drugs or available vaccines for population wellbeing. However, 
we strictly emphasised on the fact that samples were being tested to identify any 
exposure to filoviruses prior to the past EBOV epidemic.    
 




Figure 18: Flow chart of study villages and population participation.  
In total 47 villages were reached and sensitized amongst which 43 villages entirely partici-
pated, one village showed half participation (only men) and 3 villages disagreed to participat-




3.4 Participant questionnaire data 
Sample collection took place within 11 months from February to December 2017. 
Eligible participants were enrolled and sampled upon understanding and self-commit-
ment to the study. An individual consent form was signed and basic available data on 
volunteer’s age, weight, occupation, and health history were recorded prior to sample 
collection.  
In general, hunters use both traps and guns. However, following the government pol-
icies, it is forbidden for people under 20 of age to utilise guns184. So, for people under 
20 of age, traps and trained dogs are essentially used to hunt small animals such as 
rodents, rats, reptiles and birds.  Hunted animals are usually sold to bushmeat traders 
who sell to the population in small pieces either fresh or smoked. When interviewed, 
participants reported having experienced fever at least three times in the past 12 
months. Unfortunately, the only disease they had thought of was Malaria as no med-
ical consultation or diagnostic was performed. In fact, alternative medicine practition-
ers are the most consulted in these remote places. Nevertheless, only 2 people re-
ported to have experienced haemorrhaging which unfortunately remained undiag-
nosed.  
On the other hand, women are not involved in hunting activities; however, manipulat-
ing and butchering of hunted animals for food preparation constitutes their daily du-
ties. Few women reported fishing activities which is done on small rivers with a par-
ticular circular net made in circle shape. Finally, no data was recorded for excluded 
participants presenting chronic diseases and the number of EVD infected people per 
village, as this was very controversial. 
 
3.5 Chapter discussion and conclusion 
Samples were collected in selected areas which included affected and unaffected 
villages from the 2013-2016 EVD outbreak in Guinea. Study village selection was 
primary based on the accessibility and then the possible report of any EVD infection. 
The aim was to investigate the potential exposure of different villages to EBOV and 
LASV. Unfortunately, due to the limited number of samples designed for the study 
and population consent we could not bleed the same number of participants in all 
villages and this may bias results with regards to social groups involved.  
EBOV and LASV are thought to be zoonotic diseases and therefore, remote villages 
were regarded as potential source of previous infection. 
84 
 
There were various limitations to this study. Following the 2013-2016 EVD outbreak 
in Guinea, the fear and trauma in the community that usually follows1, the very limited 
access to some places and, minor resistances in the population, we could not perform 
sample collection in some potential places that were of study interest.  
To conclude, our sero-prevalence study on EBOV and LASV attempts to understand 
pre-existing exposure of the population to these viruses. It also intends to understand 
the route of infection transmission (wildlife to human) and epidemics spread (infection 
site to cities) in the population. Alternatively, research on other existing emerging dis-
ease pathogens using our collected samples could bring more understanding regard-


























 RESULTS, PREVIOUS EXPOSURE 




4.1 Enzyme linked immunosorbent assay to detect Ebola glycoprotein 
The ELISA platform was developed and described in 1971 by two Swedish scientists 
Peter Pearlman and Eva Engvall186.  To date, ELISA, also known as EIA (Enzyme 
Immuno-Assay) is wildly regarded as the most reliable immunoassay of antigen-anti-
body detection187. It is used to detect and quantify substances such as peptides, pro-
teins and hormones for diagnosis and scientific research188,189. The test utilises a re-
porter protein, typically an antibody, that is conjugated to an enzyme which changes 
colour upon reaction with a specific chemical substrate. The nature of the colour 
change depends on the enzyme-substrate reaction. For instance, the p-Nitro phenyl 
phosphate (p-NPP) turns yellow in contact with alkaline phosphatase and the strep-
tavidin-HRP (horse radish peroxidase) turns blue in the presence of TMB substrate. 
Though several types of ELISA assay have been developed over time, we performed 
indirect ELISA, as described in the material and methods, with the p-NPP for anti-
EBOV GP antibody detection. For the test sensitivity and specificity, blocking rea-
gents are used to interfere with a wide range of proteins in samples which may cause 
false positives when binding to the secondary antibody. Casein, ChonBlock and non-
fat milk have been demonstrated in interacting with several types of proteins and sub-
sequently prevent false positives in ELISA assay188.  
 
4.1.1 Detection of anti-EBOV glycoprotein antibodies using Casein as a 
blocking reagent 
517 serum samples were collected from volunteers in 44 villages across Macenta 
prefecture. We initially looked at the ability of these serum samples to bind the EBOV 
GP using casein as a blocking reagent. Casein is a milk-derived substance composed 
of proteins and amino-acid190. It was discovered to be an effective agent to block non-
specific protein binding in ELISA assay procedures. It has been used as a blocking 
and sample dilution buffer to enhance the ability to block or prevent nonspecific bind-
ings. Unfortunately, a significant amount of bacterial debris present in milk including 
different bacterial antigens such as teichoic acids still cross-react and obstruct the 
assay leading to false positives while using Casein reagent.  
We first sought to determine the range within our standard curve within which we 
would interpret sample OD values, Figure 19 shows an example of the standard 
curve with known EVD survivors’ samples. We decided to interpret sample OD values 
that fell between the upper asymptote for parameter A and the lower asymptote of 
parameter D. The upper asymptote of parameter A represents the lower limit of de-
tection (LLD) indicating the lowest concentration to be detected. It is the concentration 
level that can be different from a blank at 99% confidence level. It means that if the 
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sample and blank are tested several times, likely, the resulting brackets would ap-
proximatively be the same. Alternatively, the lower asymptote of parameter D is the 
upper limit of quantification (ULQ) which indicates the highest concentration to be 
detected. If values fell above or below these parameters, they would be classed as 
being beyond the limit of quantification and the corresponding IU/ml value to either 
the upper asymptote of A or the lower asymptote of D would be reported. Precisely, 
samples values above ULD are diluted and tested within the calibration range. 
 
ELISA assay standard curve 
 
Figure 19 : EBOV GP ELISA Standard curve 
A) Example of standard curve. Non-linear regression curve of 4 parameters (A, B, C and D), 
samples were serially diluted 1:2 with a starting dilution of either 1:100 or 1:500. B) We set a 
cut off to accept or reject values, we rejected values that fell beyond the upper confidence 
interval of parameter A or lower confidence interval of parameter D (red boxes), these values 





Following sample acquisition, we next looked to determine a cut off value which would 
distinguish positive and negative. To do this we used a known EBOV negative sample 
which consisted of pooled plasma from three native West African volunteers. This 
known negative was acquired on each ELISA plate that was assayed. To determine 
our positive and negative cut off we took the mean of all the negative plasma results 
plus 5 standard deviations from the mean and this gave us a cut-off of 0.0304 IU/ml. 
In addition to acquiring a negative sample on each plate we acquired a quality control 
which consisted of pooled plasma from three known EVD survivors and Figure 20 
shows the variation in this QC from assay to assay. 
 




Figure 20: EBOV GP ELISA negative control and QC 
A) Negative cut off is determined by taking the mean result of negatives plus 5*STD of the 
mean. This was so we could resolve positive from negative cases as stringently as possible. 
B) Variation in the QC by assay number. QC values above cut off indicate assay validation in 
daily basis. Non validated assays indicate QC value under the cut off and subsequently re-






Once we were happy with our assay platform and how we would interpret the results 
we acquired and analysed our unknown participant serum samples. Results in Figure 
21 show that 119 participants had an IgG response that was above our determined 
cut off of 0.0304 IU/ml suggesting that they may have had prior exposure to EBOV. 
When these results were broken down by affected and non-affected villages, there 
was no significant difference in terms of the magnitude in the response reported or 
the proportion of villages affected. Again, when these results were broken down by 
sex there was no significant difference in the magnitude of response, or the proportion 
of each sex affected. 
 




Figure 21 : ELISA anti-EBOV GP detection results using Casein reagent 
A)All casein results. The OD values above the cut-off indicate the presence of anti-EBOV GP 
in participant’s sample. In contrast, OD values under the cut-off indicate no response. B) Pos-
itive results by village. No major difference is observed regarding villages status either previ-
ously exposed to EVD (affected) or not (non-affected). Both show similar responses to anti-
EBOV antibody. C) Positive results by sex. Although, male and female show almost an equal 
signal of responses to anti-EBOV antibody. It follows that when exposed, both sex groups are 







We next looked to determine if there was a significant correlation between age group 
and anti-EBOV GP IgG titre, as previous reports have indicated that anti-EBOV anti-
body decrease over time115,191. It follows that people exposed about 40 years ago 
might have shown weak signal and consequently would have been below the defined 
cut off. However, as the search could not determine anti-EBOV antibody duration, 
Error! Reference source not found.Figure 22 shows that there is no correlation in 
terms of age and the magnitude of the IgG response. 
 






Figure 22: Anti-EBOV GP detection result regarding age group 
XY graph of age and IU/ml Linear regression used. This figure shows no significant correlation 














Some of the villages (16 of 44) had previously experienced EVD during the 2013-
2016 outbreak. Of these 16 villages we found 13 that showed at least one positive 
result, whereas 16 out of 28 previously non-affected villages showed an antibody re-
sponse using our ELISA platform (Figure 23).  
 




Figure 23: Map of positive cases on casein.  
Regarding both affected and non-affected villages, there is no fundamental difference of anti-
EBOV IgG response. EBOV IgG response in previous affected villages is shown in red and 
green indicates EBOV IgG response in non-affected villages. White color indicates both af-















We next looked at the EBOV anti-GP antibody prevalence using casein reagent and 
participants’ occupations (Figure 24). With regards to volunteers occupations, hunt-
ers (first contact to wildlife) and household family members (close contacts) showed 
high level of anti-EBOV antibody response. Notably, this might be related to the num-
ber of samples collected within these groups. Healthcare workers, workmen and trad-
ers showed less participation due to their limit in number in villages as the main ac-
tivities are farming and hunting. 
 




Figure 24: Anti-EBOV GP detection using casein reagent.  
High prevalence rate found in Healthcare workers, hunters and household family members as 
expected. Others occupational groups show exposure and these results relate to the number 




4.1.2 Detection of anti-EBOV glycoprotein antibodies using ChonBlockTM as a 
blocking reagent. 
Previous work has considered using various blocking buffers including Tween-20, 
BSA, normal goat serum (NGS), Casein and ChonBlock. Results indicated that 
ChonBlock is more effective in reducing several types of non-specific protein interac-
tions188,192. These experiments demonstrate that the blocking effect of 0.1% of 
ChonBlock is equivalent to 4% of BSA and 0.5% of normal goat serum blocking re-
spectively. Additionally, it proved that ChonBlock buffer can be used to block several 
types of proteins in human and animal specimens. ChonBlock then reduces back-
ground noise and other false positive results involved in ELISA assays. Finally, the 
study established that ChonBlock buffer prevent hydrophobic binding of immunoglob-
ulins to plastic surface and non-specific protein-protein interaction between antigens 
and immunoglobulins192. This reagent has helped to reduce false positive results in 
both diagnostic of infectious diseases and in the scientific research fields. Therefore, 
we next assayed those samples that were found to be positive by Casein again for 
anti-EBOV GP antibodies but this time, we blocked our plates using ChonBlock. From 
Figure 25 it can be seen that 67 out of 119 samples were found to be above the cut 
off of 0.0319 IU/ml, which was calculated based on Chonblock blocked negative sam-
ple.  
Anti-EBOV GP responses to Chonblock buffer 
 
Figure 25: Anti-EBOV antibody detection using ChonBlock reagent 
A) Magnitude of IgG response amongst ChonBlock positive samples. The cut off was consid-
ered by adding the mean of negative results to 5*STD of the mean negative result. OD values 
above the cut off indicate anti-EBOV antibody response. Subsequently, OD values under the 
cut off indicate no response to anti-EBOV IgG.  B) Magnitude of IgG response within affected 
vs non-affected villages with no significant differences. C) Magnitude of IgG response in 




In terms of the magnitude of anti-EBOV IgG response, there were again no significant 
differences between affected or non-affected areas or with sex group (Figure 26). 
 




Figure 26: Anti-EBOV IgG response in study villages by ChonBlock reagent 
GIS map of affected and non-affected villages that showed IgG response to ChonBlock rea-
gent or not. EBOV IgG antibody was broadly detected in the study zone. Red color indicates 
EBOV IgG response in previous affected villages and green indicates EBOV IgG response in 
non-affected villages. White color indicates both affected and non-affected villages with no 





4.2 Detection of anti-EBOV antibodies by Western blot 
We next looked to confirm our EBOV ELISA findings using an additional assay plat-
form. Western blot is an effective method used to detect and characterize specific 
proteins of interest in a complex mixture of proteins156. It is wildly used in research to 
identify specific proteins of interest regarding their molecular weight in a complex mix-
ture of proteins extracted from cells or tissues154. Proteins are run on an SDS-PAGE 
gel and separated according to their sizes and molecular weight. Proteins are then 
transferred to a PVDF or nitrocellulose membrane and enzyme conjugated antibodies 
are added to the membrane, bands are visualized by addition of an appropriate sub-
strate and samples are acquired using Bio-RAD molecular imager (CHemi-
DocTMXRS+ Imaging system) (Figure 14). We used the Western blot technique to 
confirm our positive samples from ChonBlock ELISA results. We determined previous 
exposure to EBOV and the generation of antibodies reacting to EBOV GP, NP and/or 
VP40. Notably, the VP40 matrix protein of EBOV is abundantly expressed in viral 
infection193. VP40 along with GP and VP24 are membrane associated proteins and 
contribute to viral replication. On the other hand, NP associates with VP30, VP35 and 
L proteins to form the virus nucleocapsid and plays an important role in genome tran-
scription and replication23. It follows that targeting anti-NP and anti-VP40 antibodies 
as well as anti-GP antibodies would bring more accuracy in anti-EBOV antibody de-
tection in our Western blot assay. As these three proteins constitute major viral anti-
gens, Hafmann et al performed a serological analysis targeting those proteins in EVD 
survivors and their close contacts in Sierra Leone194. A commercial ELISA kit was 
used for protein detection and report indicated 97.7% of EVD survivors have antibody 
levels against GP, NP and VP40 proteins either singularly or coupled (GP/NP, 
GP/VP40, or NP/VP40) or tripled (GP/NP/VP40).  
The 67 samples previously tested positive to EBOV GP by ELISA assay (ChonBlock 
reagent) were tested by Western blot. Before acquiring data on volunteer samples, 
we looked to confirm the specificity of our secondary detection antibodies. In Figure 
27, it can be seen that monoclonal antibodies specific to GP, NP or VP40 showed 
specificity and did not cross react with other EBOV proteins. GP is visualised at 100 












Figure 27: Specificity of EBOV monoclonal antibodies.  
A) Control antibodies to show specificity in interacting with selected antibody in EVD survivor’s 
serum.  B) Show QC and NEG controls results for assay validation. Purified EBOV GP, NP 
and VP40 proteins were subjected to SDS-PAGE and Western blotting. Blots were probed 
with monoclonal antibodies specific to the indicated EBOV proteins as well as with a QC 
standard from survivor serum and a Negative control from uninfected serum. No cross reac-










In addition to testing the specificity of our monoclonal antibodies, Figure 27 also 
shows that our QC plasma has a detectable GP, NP and VP40 response whereas 
negative control plasma does not. Notably, the QC plasma is a pool of three EVD 
survivors’ serum whereas the negative plasma is a pool of three non EVD subjects. 
We next analysed our participant samples that showed a positive result by ELISA and 
it can be seen in Figure 28 that 11 samples out of the 67 tested clearly showed a 
response to one or more EBOV proteins. When the samples’ ELISA value (by 
ChonBlock) are highlighted it can be seen that they are not all the maximum respond-
ers and that they cover a broad range of values. With regards to Western blot method 
specificity and sensitivity to detect and characterize specific protein/antibodies of in-
terest195; it is evident that those 11 samples were from people who experienced EBOV 
infection in our study cohort.   
Anti-EBOV GP responses on Western blot 
 
 
Figure 28: EBOV GP protein detection by western blot  
A)Western blot of those deemed to show a response. B) red dots indicate the ChonBlockTM 
ELISA result from the Western blots in A. C) Representative example of Weston blot mem-




Of 44 villages included in the study, 11 show antibody detection through Western blot 
assay amongst which five villages have reported EVD (affected) and five villages 
have never reported EVD (non-affected) during the 2013-2016 outbreak. Table 7 
gives breakdown of these participants location, age and sex group. It can be seen 
that they originate from 5 affected and 5 non-affected villages and that there were 7 
females and 4 males. 
Table 7: Table showing the 11 participants with detectable western blot bands to at Least the 
GP. 
 
   Villages that responded to anti-EBOV GP detection on WB 
 
Figure 29: Anti-EBOV IgG response in study villages by Western blot   
GIS map of affected and non-affected villages that showed and IgG response to Zaire ebo-
lavirus GP by Western blot test. Both affected and non-affected villages show anti-EBOV re-
sponse with no major differences.  
 
Sample ID Sex Age Village Village status 
ChonBlock™ 
ELISA 
JB455 M 45 Iyezou Affected 4.211 
JB472 F 45 Fassankoni Affected 3.742 
JB353 M 45 Namouyapoulou Unaffected 0.683 
JB205 M 57 Vassaizeazou Affected 0.376 
JB443 M 25 Zenie Affected 0.366 
JB489 F 39 Sassaguizezou Unaffected 0.232 
JB490 M 60 Sassaguizezou Unaffected 0.227 
JB171 M 57 Dohomai Unaffected 0.221 
JB211 M 70 Baizea Unaffected 0.087 
JB125 F 40 Sovaou Unaffected 0.035 




Interestingly, as it can be seen in  Figure 288 not all samples were positive for all 
EBOV proteins. We reported on the 11 participants that were positive to EBOV GP; 
however, there were 33 participants that were positive to NP and 18 positive to VP40. 
Those that were positive for EBOV GP were not necessarily positive for other EBOV 
proteins, in fact, only three participant samples were found to show activity against all 
three proteins. 
 
Quantified anti-EBOV proteins detected on Western blot 
 
 
Figure 30 : Ebola virus proteins detection.  
Bars and numbers in red indicate the number of participants showing anti-EBOV antibody 








Our data suggests that 2.12% (11 of 517) of participants show an anti-EBOV GP 
response, which is contradictory to our ELISA findings. The ability of ELISA assay to 
effectively block different types of non-specific reactions is poorly understood with 
regards to numerous proteins in specimen and the high binding affinity of proteins to 
plastic surfaces187,196. Consequently, a supplementary assay, Western blotting, which 
is identified for its high sensitivity and specificity at a molecular level of protein detec-
tion has been developed195. This assay was then performed subsequent to ELISA 
assay positivity.  
Regarding sample collection areas, anti-EBOV IgG detection was nearly similar in 
unaffected villages 21.42% (6 of 28) and affected villages 25.00% (4 of 16) with re-
gards to the number of samples collected per zone. Western blot data taken on its 
own would suggest that 22.72% (10 of 44) show antibody response to EBOV. Con-
sidering antibody response via ELISA assays using both Casein and ChonBlock rea-
gents and Western blot analysis, our findings established evidence of either mild or 
asymptomatic EBOV infection occurring in several villages.  
 
4.3 Multiplex beads assay data for Ebola virus proteins detection 
ELISA and Western blotting have been the most reliable assay for protein detection 
and quantification. However, they are not well equipped to measure simultaneously 
several analytes in a single reaction197. Multiplex beads array assays have been re-
cently developed to measure proteins and other analytes in both research and clinical 
laboratories198. The potential benefit of the assay is its ability to evaluate multiple pro-
teins or analytes in a small volume of biological material. The assay results are often 
read on flow cytometry instruments (e.g. BD AccuriTM C6 Plus). Flow cytometry in-
struments detect, measure and analyse thousands of cell populations or particles per 
second199. Cells or particles are labelled with fluorescent markers and injected into a 
flow cytometry instrument. When passing through a laser beam, light scatter identifies 
a target population by their phenotypic markers and the data produced is computer-
ised. Our in house beads array assay is a multiplex technology (immunoassay) which 
determines simultaneously immunoglobulin isotype to various proteins in human 
specimens. The assay uses magnetic beads to capture and measure multiple pro-





4.3.1 Multiplex beads assay results 
The 67 samples which show antibody response on ELISA and were tested on West-
ern blot were re-tested using our multiplex bead array assay. This assay detects pro-
teins and analytes in a small volume of patient’s specimen. First, carboxyl magnetic 
beads (color coded) were coated with EBOV GP tetramer (0.35mg/ml). Volunteer se-
rum samples and coated beads were mixed, and existing anti-EBOV antibodies could 
then bind to the EBOV GP antigen. Further, the detection antibody (anti-human IgG-
PE, 100 mg/ml) conjugated with biotin was added and specifically binds to the anti-
EBOV antibody. Later, streptavidin-PE substrate was added which subsequently 
binds to biotin on the anti-human IgG-PE detection antibody. Finally, the mixture is 
read on a dual-laser flow cytometry-based instrument, BD Acuri C6 Plus flow cytom-
eter. While passing through the laser, beads are classified regarding the analyte de-
tected (side scatter) and the magnitude of PE-derived signal (forward scatter)198. (Fig-
ure 15). 
 
4.3.2 Detection of Anti-GP IgG isotype 
We next look to determine the isotypes involved in suspected EVD survivor samples. 
Work performed by Davis et al on the human B cell response to EBOV infection 
looked at the dynamic changes in IgG subclass of EBOV antibodies after infection200. 
The data established that when EVD patient is discharged IgG1 is high and decreases 
slowly over time, IgG2 remains undetectable, IgG3 is high and decreases rapidly, 
IgG4 is undetectable but appears later about 1-2 years post-infection.  The study has 
then suggested that the long-term IgG response switches to IgG4 over time. 
To determine the specificity of the assay we conjugated our recombinant EBOV GP 
to carboxyl magnetic beads. To check the specificity of these conjugations we used 
the monoclonal antibody KZ52 as well as EVD survivor QC and negative control 
plasma. KZ52 is an antibody derived from EVD survivor (Kikwit, 1995) which neutral-
izes EBOV when specifically bound to viral glycoprotein (GP1/GP2)201. It is likely that 
KZ52 requires both GP1 attachment subunit and GP2 pre-fusion conformation subu-
nit for proper binding to viral surface202,201. This enhances KZ52s specificity to recog-
nize and bind to anti-EBOV antibody and subsequently make it an antibody of interest 
for virus neutralisation 202. 
It can be seen from Figure 31 that negative plasma shows a background fluores-
cence between 102 - 103 mean fluorescent intensity (MFI) whereas both QC plasma 
and KZ52 show a strong positive signal between 104 - 105 MFI, whereas in all cases 
the isotype control (grey) shows a base level of 102 MFI. 
102 
 




Figure 31: Bead isotype array set up 
A)QC plasma, B) KZ52 antibody, C) Negative plasma. Representative flow cytometry of 
plasma control (QC) and antibody (KZ52) showing strong anti-IgG isotypes response (red 
peak, A and B while negative control plasma with no prior exposure to EBOV show no anti-








Once we were convinced that the beads had GP, NP or VP40 bound to their surface 
and that they showed specificity, we next looked to run participant samples using this 
assay format. We acquired data on 67 samples that we have previously shown by 
Western blot and/or ELISA to have had prior exposure to EBOV. Results in Figure 
32 suggest that not all samples show robust anti-GP IgG responses, four of the total 
anti-GP IgG responses appear to be the same level as the negative control whereas 
the remaining samples that showed high IgG levels to EBOV GP showed mixed re-
sponses to EBOV NP and VP40. 
 





Figure 32: EBOV anti-IgG response 
A) GP total IgG. B) NP total IgG. C) VP40 total IgG. APC beads were conjugated with target 
EBOV protein then incubated with EVD survivor plasma, QC or negative control plasma (N). 
Samples were washed and acquired on a flow cytometer, data reported shows the individual 
results and the mean MFI and SEM. Mann-Whitney was used to test for significance P=<0.05. 







In addition to obtaining multiplexed data on the total IgG response we were also able 
to probe the IgG isotypes that make up the total IgG response to EBOV GP. In Figure 
33, it can be seen that IgG1 is the dominant isotype amongst our sero-positive par-
ticipants and that responses to IgG2-4 were mixed. Again, there were four participants 
that showed no or minimal response in our assay with regards to IgG1 subclass de-
tection. 
 





Figure 33: GP beads, IgG subclass binding.  
Breakdown of the EVD survivor IgG sub type response to EBOV GP. APC beads were conju-
gated with EBOV GP protein then incubated with EVD survivor plasma. Samples were washed 
and acquired on a flow cytometer, data reported shows the individual results and the mean 











4.4 Chapter discussion 
This study is the first to investigate anti-ebolavirus IgG responses in the population of 
the forested region of Guinea, Macenta zone. Limitations to this study could include: 
a short life expectancy in the population (mainly amongst men)97, anti-ebolavirus IgG 
decreases over time and the increase of wildlife disappearance due to human behav-
iour which result in climate change202,203. Previous reports have established EBOV 
neutralising capacity up to 14 years after infection202. However, antibodies may cross 
react in ELISA assay as demonstrate by Eric Nakayama et al. while investigating 
ELISA for the detection of filovirus species-specific antibodies186. The study used His-
tagged secreted forms of the transmembrane glycoproteins (GPs) of five ebolavirus 
species and one marburgvirus specie as antigen. Report indicated notable cross re-
activity in human and NHPs serums whereas a little cross reactivity was observed in 
mouse sera both previously exposed to EBOV or MARV. Our study volunteers over 
55 (n=4) who show anti-EBOV antibody response may have been exposed years 
ago. It is unfortunate that we could not determine the duration of the exposure through 
antibody characterisation. Initial experiments using Casein provided the greatest 
number of seropositive cases, however additional experiments using a more reliable 
blocking buffer, ChonBlock™, reduced this number from 119 to 67. Though 
ChonBlock is more accurate than the Casein reagent the stringent assay cut off used 
(5*STD) might have also contributed to decrease the number of positive cases. 
Both EVD affected, and unaffected villages showed evidence of EBOV anti-GP anti-
body detection without clustering at any particular location. In fact, the shortest dis-
tance between two villages of the study is about 5 km. This could possibly enhance 
the dynamic of wildlife colonies circulation in the zone and infection spill over in com-
munities. Considering that there are no ecological differences between zones, it is 
suggestive that an unknown EBOV or related filovirus reservoir might have been cir-
culating in the zone for decades. 
Importantly, it is hard to determine whether the positive cases seen in the affected 
villages resulted from sub symptomatic or mild EVD infection of the 2013-2016 out-
break or it is an evidence of unknown EBOV late transmission in the region.  
Sex group distribution shows no significant differences of seropositive; which was 
unexpected since males are known to be the first line of exposure through hunting 
activities. However, women are exposed via domestic activities such as butchering, 
skinning, smoking meat, eating, cooking and can be bitten, scratched or exposed 
when, manipulating or picking up dead animals’ carcasses. An infection may also 
occur when cutting themselves with knife or an infected animal bone.  
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There is some discrepancy between experimental approaches, and it follows that de-
veloping an acceptable, sensitive and specific assay for antibody characterisation 
would aid in accurate identification of historical infections. In addition, the discovery 
of a potential EBOV reservoir will help to prevent community exposure and reduce 
the likelihood of future EVD and related outbreaks. 
Our Western blot and Multiplex bead assay data suggest that those that are positive 
for antibody to EBOV GP are not necessarily positive for antibodies to NP or VP40. 
Moreover, comparing ELISA assay results to Western blot, it is evident that in an 
ELISA the protein is not denatured whereas it is during SDS-PAGE for Western blot. 
So, if human antibodies are best at detecting native proteins, they would work much 
better in ELISA than Western Blot. Western Blot data is great for confirming, but the 
ELISA data is likely more accurate in terms of actual numbers of seropositivity 
detection within population. However, Mulangu et al conducted a serosurvey study to 
detect anti-EBOV antibodies in human using a full-length of recombinant NP (r-NP) 
through ELISA assay204. The selection of viral NP detection was due to its abundancy 
in viral particle and most importantly the level of host antibody response to this 
protein. The study was performed in Sankuru district in the DRC amongst healthy 
population (n=3415) to assess animal exposures and people behaviour with regards 
to EBOV antibody prevalence. The data reported 11% of population exposure to 
EBOV. Alternatively, we found that a large number of our participant samples were 
positive to EBOV NP and moderately for VP40 proteins. Therefore, we would suggest 
that future seroprevalence studies look at multiple EBOV targets to minimise the 
chance that we are seeing cross reactivity from other circulating pathogens. 
In conclusion, our findings indicate the possible circulation of EBOV or a related filo-
virus with mild or asymptomatic unreported symptoms in the Forested region of 
Guinea. Unfortunately, there have been no available data regarding EVD surveillance 
in the zone due to lack of diagnostic facilities before the 2013-2016 outbreak. Cur-
rently, following the West African EVD outbreak which primarily started in the zone, a 
haemorrhagic fever diagnostic laboratory (EMLab) has been established in the for-
ested region of Guinea for infectious disease surveillance. The EMLab analysis plat-
form include EBOV, MARV, LASV, yellow fever and dengue. Additionally, similar se-
roprevalence study performed in Cameroon established the presence of anti-EBOV 
antibodies among healthy farmers with no prior EVD reported116. From our findings, 
it is unfortunate that we could not determine whether these detected antibodies relate 
to the past 2013-2016 EVD outbreak in the zone or from an unknown late transmis-
sion. Since the level of anti-EBOV antibody in both affected and unaffected villages 
is consistent and considering that the ecological system is broadly identical in the 
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zone, we suggest that the virus reservoir might have been subject of hunting in the 
zone for decades. 
More investigations are needed to identify the EBOV reservoir and further studies to 
better understand Ebolavirus infection and circulation in the forested region of 
Guinea. Those studies should be conducted with no restriction regarding volunteers’ 
age group, occupations and locations. The recent discovery of BOMV in Sierra Le-
one12 indicate the possible circulation of unknown ebolavirus species that may cross-


































In order to determine the prevalence of LASV in Macenta prefecture, we performed 
ELISA to identify the presence of LASV antibodies in our study samples. We used 
the Blackbox LASV IgG ELISA’ kit from BNITM in Germany. The kit is designed for 
qualitative serological detection of acute or past LASV infection. The kit includes pos-
itive and negative controls, blanks and background levels/noises were added to mon-
itor non-specific bindings. In the blank wells, no serum was added in order to measure 
detection antibody (secondary antibody) interaction with ELISA plate plastic surface. 
Although, background wells were LASV antigen free in order to measure specimen’s 
wild proteins binding to ELISA plate.  
LASV antibody prevalence varies significantly between studies. In 2009, a broad 
search on LASV sero-survey conducted in Guinea including the main geographic re-
gions of Guinea established high prevalence rate of 25-55% in the Forested and sa-
vannah regions of Guinea135. This high prevalence in forested region might be asso-
ciated with the presence and consumption of rodents which are largely distributed in 
communities including the M. natalensis a known reservoir of LASV. In contrast, the 
lower prevalence of 7 %, was found in the middle and lower regions of Guinea. These 
regions encounter less contact with rodents as consumption is forbidden for religious 
proposes. However, infections in those regions are probably associated with food or 
materials contaminated by infected rodents’ fluids and feces. Another study per-
formed in Guinea at Gueckedou, Lola and Yomou prefectures indicates 12.9% of 
sero-positivity to LASV in rural areas and 10% in urban areas136. Further, LeCompte 
et al performed RT-PCR in rodents in Guinea (n=1482) and reported a prevalence 
rate of 1.2 % for LASV. The study established that M. natalensis might be the only 
LASV reservoir in Guinea132. Notably, one sporadic LASV infection disease case was 
notified in Mamou in January 29, 2019134. Active contacts tracing and follow up likely 
indicated no further contamination within close relatives and healthcare workers.   
 
5.1.1 LASV seropositive rate in Macenta zone 
In total, 517 blood samples were collected from EVD reported and unreported areas. 
Samples were tested for anti-LASV IgG and Figure 34 shows that out of the 517 
people tested 302 were found to be positive for LASV antibodies. As stated in the 
protocol, the assay cut-off was calculated using the following formula: Sample result 
(index value) = OD450-OD620(sample)/OD (cut-off) where the cut off value is calcu-
lated: Cut off = OD (neg average) + 0.150, Negative and positive controls were pro-
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vided with the kit. Positive samples (Index value ≥ 1.00) suggest past or current in-
fection with LASV and negative samples (Index value ≤ 0.90) indicate no anti-LASV 
antibody was detected. However, as the antibody is detectable only after two weeks 
of LASV infection, additional testing or clinical findings should be considered135. 
 




Figure 34: Lassa virus IgG detection in Macenta prefecture  
Serum samples were processed and analysed as described in the Blackbox® assay protocol. 








When we mapped the seropositive result, it could be seen that cases were fairly dif-
fused across our sample collection sites (Figure 35). However, in few sites we re-
ported no anti-LASV antibody detection. Those unreported areas seen presented a 
few numbers of volunteers’ participation with a total of 1 to 3 samples collected. We 
then assume that these seronegative results might have been caused by a lower 
participation rate in those places. 
 
LASV seropositive results map 
 
 
Figure 35: Localisation of LASV seropositive cases in Macenta 
Spatial locations of LASV antibody seropositivity in Macenta prefecture. Positivity rate re-
ported are simultaneously linked to the number of samples collected in each place.  Places 







5.1.2 Lassa virus prevalence regarding age, sex and occupation groups 
Males are likely considered to be more exposed to zoonotic pathogens due to their 
hunting activities. However, as LASV reservoirs are broadly spread in the region and 
closely share home habitats with people, human contamination often occurs when in 
contact with infected rodents’ fluids or faeces. Consequently, there is no restriction of 
exposure to LASV infection in community (Table 8).   
 
 
Table 8: Occupational data for study cohort participants.  
High participation rate was respectively found in hunters group and household family mem-
bers. Other activities are less practised in villages. Notably, no more than 2 healthcare workers 
are found in one village. 
 
Occupation Male Female 
Hunters 242 0 
Household member  29 211 
Healthcare worker 23 11 
Workman 26 0 














Our data findings resulted in hunters (59.91%, 145 of 242), households family mem-
bers (58.29%, 116 of 199), healthcare workers (58.82%, 20 of 34), workmen (34.61%, 
9 of 26) and traders (75.00%, 12 of 16). We found no major difference regarding sex 
group distribution and our data show 58.84% (166 of 292) in men and 60.44% (136 
of 225) in female. We also did not see any significant correlation between age and 
LASV exposure (Figure 36). 
 
Age group exposure to LASV 
 
 
Figure 36: Age vs Anti-LASV IgG detection  
Graph showing participant age vs ELISA in Index value (IV). The data show no sig-

























5.2 Chapter discussion and conclusion 
In this chapter, LASV-specific IgG antibodies were detected via ELISA test. The assay 
was performed using the BLACKBOX LASV IgG kit from BNITM as per the manufac-
turer’s instructions.  
Though bushmeat hunters and household family members represent our study’s main 
target, people with other occupations such as healthcare workers, workmen and 
bushmeat traders were involved in the study. LASV is mainly spread through infected 
rodent fluids and materials (faeces). Despite its high prevalence in Macenta prefec-
ture as previously reported in studies, Lassa haemorrhagic fever (LHF) infection dis-
ease has never been reported in the zone. Furthermore, regarding LASV diagnostic 
unavailability, hospitals in forested region of Guinea as Gueckedou, Macenta and 
Nzerekore might have encountered mild or asymptomatic unreported LASV cases137. 
The disease is often attributed to other tropical diseases such as malaria, yellow fe-
ver, influenza or typhoid fever. Therefore, developing LASV diagnostic capability for 
early detection in the zone is needed to avoid disease spreading throughout the com-
munity. Recently, in September 2018, one LASV infection case was suspected in 
Mamou and was laboratory confirmed in the capital city,  Conakry134. Investigations 
later indicated that the subject originated from Kissidougou prefecture a town located 
at 180 km from Macenta.  
Our study established 58.41% of LASV IgG detection in the population. It was con-
ducted in a probable endemic area regarding the presence of LASV reservoir (M. 
natalensis).  Study villages were randomly selected and the prevalence of LASV we 
found is likely to be representative of the local population in the zone. Koivogui et al 
reported 40% seropositivity to LASV in Faranah, the upper region of Guinea205. These 
findings were similar to those of Knobloch et al in Liberia (1982)206 and McCornick et 
al in Sierra Leone (1987)207. The fact that LHF outbreaks do not occur in the zone 
may possibly be due to a milder LASV strain being in circulation in the zone or popu-
lation genetics; however further works would be needed to confirm this. Alternatively, 
LASV pathogenicity regarding virus strain variation has been studied by Bowen et al 
in 2015208 and M.D. Bowen, P.E. Rollin et al in 2000138. In addition, an experimental 
study using live LASV on animals to evaluate strain virulence was performed in Libe-
ria by Jahrling et al 1985209. These studies have brought great insight about LASV 
pathogenicity in humans. Moreover, a broad range of non-pathogenic Arenavirus cir-
culating may cross react in ELISA and it is not clearly defined why some Arenaviruses 




Our findings provide significant insight into LASV circulation in Macenta prefecture 
with no report of LHF infection outbreak. Further investigations on both human genetic 
makeup and LASV strain virulence should be conducted in forested Guinea to estab-
lish the potential reason for high LASV sero-positivity with low incidence of LHF ab-
sence in the zone. 
With regards to LASV diagnostic challenges due to multiple LASV strains occurring 
in different regions, there has not be a validated assay to date170. It follows that one 
future strategy could be developing and validating LASV diagnostic assay perfor-
mance according to geographic regions. Nevertheless, the BLACKBOX LASV IgG 
ELISA kit was developed using human serum and worked well in our assays. But 
unfortunately, the assay performance characteristics using blood, plasma, hemolyzed 
and icteric specimens have not been determined yet. As a result, using the BLACK-
BOX LASV IgG ELISA kit with icteric or hemolyzed serum in our study samples might 















6.1 EBOV circulation in the forested region of Macenta 
From the results we presented in chapter three we would conclude that a number of 
EBOV infections, whether sub symptomatic, mild or unrecognized, may have oc-
curred in remote rural villages deep in the forest and near large rivers within the for-
ested region of Guinea. Within the forested region of Macenta there is poor healthcare 
and little record keeping with regards to infectious disease, therefore, we believe that 
this is the first such seroprevalence study on filoviruses to take place in the forested 
region of Guinea in Macenta prefecture.  
Throughout this study, several challenges such as poor terrain and local sensitisation 
difficulty aroused. In addition, a lack of educated people in villages, absence of pop-
ulation awareness about haemorrhagic fever diseases, stigma associated to EVD 
disease, poor healthcare facilities in villages and difficult movement in the zone con-
stitute major challenges to overcome.  
We selected affected (previous report of EVD) and non-affected (no previous report 
of EVD) villages to evaluate exposure to EBOV via bushmeat hunting, manipulation 
and consumption. Community healthcare agent involvement and prefectoral health 
sanitary records contribute to identify whether villages were affected or non-affected 
with the past EVD outbreak of 2013-2016 in this zone. Unfortunately, these records 
are archived in DPSs and probably in the national health system but not published. 
Notably, DPSs monthly report health situation of their record to the ministry of health 
office in Conakry. We proposed a questionnaire to volunteers which provided im-
portant information about each participant regarding their age, locations, historical 
health issues, occupations and personal involvement and wildlife contact. To our 
knowledge, no such questionnaire had been used in previous studies. However, as 
this was the first seroprevalence study in the zone and with regards to the study target 
population exposure to EBOV infection, these questionnaires played a key role in 
selecting eligible volunteers. A total of 517 volunteers were questioned and blood 
donors would sign a consent form prior to sample collection. We performed ELISA 
using EBOV tetramer antigen from Oxford University. Furthermore, western blot and 
flow cytometric assays were performed to support our ELISA findings and to look for 
an antibody response to additional EBOV proteins. As part of our ELISA studies we 
used two blocking buffers to minimise background, ChonBlock buffer was found to 
give the lowest level of background noises. We used very high cut-off to define our 
sample positivity (5 times the standard deviation from the negative control mean). 




Furthermore, our positive samples were performed on Western blotting and multiplex 
beads arrays assay. In total 67 samples were assayed on both tests. Western blot 
analysis additionally assayed for NP and VP40 proteins. A large number of samples 
showed detection to NP proteins (33 of 67 samples tested) and VP40 protein was 
detected in 18 samples. The abundance of NP protein detection may be related to its 
high level in viral particles and it has robust antigenicity191. However, EBOV GP is 
responsible for critical pathogenic differences among viral species212. Consequently, 
EBOV GP should be targeted as potential endpoint for EBOV infection establishment. 
In addition, we tested our sample on multiplex beads array and encountered signifi-
cant IgG isotype response. The dominant IgG isotype was found to be IgG1 while 
IgG2-4 response were mixed. 
Our findings suggest that 12.96% of participants showed a response to EBOV GP by 
ELISA using ChonBlock blocking buffer. These findings include both EVD affected 
and unaffected villages. On the other hand, we performed Western blot analysis to 
reinforce our positive samples from ELISA. We found only 2.12% of seropositivity with 
regards to anti-EBOV antibody response to EBOV GP. In both assays, we used a full 
length of EBOV antigen but found significant difference in antibody detection. Similar 
studies performed in Sierra Leone indicated significant differences in EBOV antibody 
detection using different methods. For example, Hearn et al performed IgG antibodies 
testing to specific viral pathogens in Kenema general hospital and found 5.2% sero-
positivity to EBOV and 50.2% to LASV 213. Simultaneously, IgG antibodies were de-
tected for other pathogens such as MARV-VP40 (10.2%), RVFV-NC (1.8%), CCHFV-
N (2.0%), flaviviruses (52.9%) and alphaviruses (55.8%). Samples were collected 
from admitted people in Kenema government Hospital (KGH) in Sierra Leone for 
acute haemorrhagic fever illness and a multiplexed bead-based system (the MAGPIX 
platform) was performed for antibodies detection. Additionally, Halfmann et al de-
tected EBOV GP antibodies in 34 volunteers over 267 giving 12.7% among EVD close 
contacts in Makeni, Sierra Leone194. These findings suggested that these people 
might have experienced mild or asymptomatic EVD infection. Unlike these studies 
performed in Sierra Leone, we collected our samples amongst highly exposed people 
to zoonotic pathogens, bushmeat hunters and household family members with no 
report of any illnesses. With regards to this significance differences of antibody de-
tection between assays, developing a reliable and standardized accepted assay for 




Our study was specifically tailored to occupational groups involving hunters and their 
household family members, workmen, bushmeat traders and healthcare. Respec-
tively, our findings indicate bush meat hunters 2.48% (6 of 242), household family 
members 2.50% (5 of 199) and healthcare workers 5.88% (2 of 34) have been ex-
posed to EBOV. In contrast, there was no antibody detection in workmen and traders’ 
groups. However, it is important to note that these differences in antibody detection 
within occupational groups may be associated with the number of samples collected. 
It is unfortunate that we could not establish whether this prevalence is related to a 
specific animal hunted or associated with population occupations in the zone and this 
may be an avenue of future research. 
Considering previous exposure to the virus in population, we found no major differ-
ences between affected and unaffected villages. Positive cases were found right 
across the study zone, suggesting there was no localised hot spot. These findings 
may be related to the ecological conditions in the zone which might result in the easy 
circulation of the virus reservoir species or intermediate host at low level. Although, it 
might be associated with movement of exposed people from affected places during 
the past 2013-2016 EVD outbreak in the zone. Those people might have experienced 
a subclinical EBOV infection. Notably, the area found in our study with the highest 
concentration of seropositive people may be related to the high number of samples 
collected compare to other locations. Especially, the chosen area is a non-affected 
village located deep within the forest. Also, it is the native village of the principal in-
vestigator of this study which could have played a key role in greater participation. It 
is important to note that volunteers were randomly selected and could include at least 
one couple from each family within the village. Future studies should consider includ-
ing all villages in Macenta prefecture without restriction as this may result in more 
anti-EBOV GP detection in the zone. Nevertheless, in the study zone, the shortest 
distance between two villages is about 3 to 5 km. This explains the high connectivity 
between villages which enhances disease spread in community through human to 
human contact in the event of first exposure (index case).  
Although, EBOV is widely known as zoonotic infection; however it remains unclear 
whether viral infection occurs directly from the virus  reservoir or through an interme-
diate host which might be considered as virus amplifier214,215. Nonetheless, to date 
bats are thought to be an EBOV reservoir. During participant interview we found no 
particular activity related to bat manipulation in the zone. Commonly, bats have been 
subject of hunting and consumption in the entire study zone over past years. Our 
search established high antibody detection in hunters and household family mem-
bers. Those people seem to be in daily contact with a variety of wildlife consequently 
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have higher exposure rate to potentially infected animals. Rimoin et al performed a 
statistical analysis to investigate population exposure to wildlife via daily occupa-
tions214. The study was done in general population (n=4574) and include 14 villages 
in Sankuru district in the DRC. The data reported population exposure to wild patho-
gens through eating, cooking, butchering and hunting. So, the association between 
wildlife contact and people’s occupations with EBOV antibody detection via laboratory 
analysis should be thoroughly investigated for possible reservoir or intermediate host 
existence.  
Our study is likely the first to demonstrate the possible circulation of EBOV prior to 
the 2013-2016 EVD outbreak in Macenta zone of Guinea.  Similar serologic survey 
of rural population was performed in Gabon and involved 4,349 volunteers from 220 
villages191. The study was conducted to understand EBOV circulation and transmis-
sion to human and includes both epidemic and non-epidemic regions. Collected sam-
ples were assayed using an ELISA method with Zaire ebolavirus antigen and estab-
lished 15.3% seropositivity to EBOV IgG antibody. In addition, to better understand 
EBOV IgG reactivity, the study applied Western blot techniques with 138 samples 
that previously show antibody response on ELISA. The assay revealed 21% of anti-
body response to at least one EBOV proteins including GP, NP, VP40, VP30 and 
VP24. In contrast to the Gabon study, which was performed with regards to ecological 
factors, we conducted our study regarding previous exposure to EVD and population 
risk factors with regards to habitat and occupation. Unfortunately, our selected vil-
lages share similar ecological environment; therefore, we could not differentiate the 
variation of EBOV prevalence in the zone. 
Our seroprevalence study conducted in Macenta prefecture, in forested Guinea to 
determine the possible circulation of EBOV prior to the 2013-2016 West African EVD 
outbreak provided novel data. Our data likely represent the level of prevalence of 
EBOV in both affected and unaffected areas. Regarding the high case fatality propor-
tion associated to EVD, our seroprevalence results might be associated either to the 
past EBOV infection or a pre-existing unrecognized infection in the zone. A potential 
limitation to the study is that we failed to get information on previously unknown haem-
orrhagic deaths in those villages and this kind of information could have helped sup-
port the view that EBOV is in circulation at low levels. Considering the possible pre-
exposure to EBOV, these unreported cases might have been linked to (i) a minor 
exposure to the virus which might have been cleared-up by  host immune-response 
(ii) an exposure to known or unknown species or related filovirus of less pathogenicity 
circulating in the zone, such as RESTV which is known to be asymptomatic in humans 
and NHPs (iii) finally, it might be associated to a cross-reactivity to virus-like particles 
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which generally produce several nonspecific bindings of the antibody and conse-
quently leading to false positive reaction216.  
To conclude, since early EVD symptoms are non-specific and are similar to that of 
many tropical illnesses such as malaria, influenza or typhoid fever, EVD may often go 
undiagnosed and consequently not reported. Providing available diagnostic facilities 
such as molecular diagnostics in communities of the forested region of Guinea could 
greatly help to prevent EVD outbreak spill over event by early detection of occurring 
infection. Although, regarding the persistence of stigma in the population associated 
with EVD, adequate outreach is crucial in preventing population mistrust for future 
epidemiological studies in outbreak zones. 
 
6.2 Lassa virus IgG antibody detection 
West Africa is a home-based to numerous pathogens but well-trained staff and proper 
infrastructures for disease surveillance are severely limited. Thus, understanding dis-
ease prevalence in a region is necessary in order to make appropriate preparations. 
Such preparedness could include an effective diagnostic system, proper care and 
treatment of infected people. These would help to reduce disease transmission and 
spill over in communities.  
In the forested region of Guinea, the population often suffer and die from several viral 
diseases whether known or unknown. Therefore, knowing about febrile illnesses and 
diagnosing the causative agent early will contribute to controlling diseases and pre-
vent an outbreak occurrence in communities. In order to determine the prevalence of 
LASV circulation in Macenta prefecture, we applied a serological assay (ELISA) on a 
panel of 517 serum samples collected mainly among hunters and household family 
members in remotes rural areas. Little is known with regards to LASV prevalence in 
this area and we hoped to add to this limited body of information. Selected study 
areas were composed of villages with previous report of EVD infection and villages 
with no previous report of EVD infection. However, to date there have been no previ-
ous report of LASV infection in the entire study zone and surrounding environment.  
We analysed our samples using recombinant Lassa virus nucleoprotein (r-NP), which 
is an antigen from the BLACKBOX kit, to detect specific anti-LASV IgG antibody. This 
kit is known to be efficient and valuable for qualitative detection of LASV IgG antibody 
in human and non-human primate. It is being manufactured by BNITM and provides 
serological evidence of an acute or past LASV infection.  
122 
 
Using this kit our data indicates 58.41% seropositivity to LASV which gives strong 
evidence of population exposure to the virus in Macenta prefecture. Regarding the 
literature, we found that LASV antibody prevalence varies significantly between stud-
ies and assays performed. In July 1993, a broad search on LASV prevalence in 
Guinea which included the main geographic regions of Guinea established high prev-
alence rate of 25-55% in the forested and savannah regions of Guinea217. The study 
performed ELISAs using LASV nucleocapsid protein as the antigen of choice. It was 
found that there was a high prevalence of anti LASV -NP antibodies amongst samples 
from the Forested and Savannah regions and this might be associated with the pres-
ence and consumption of rodents in those communities. These rodents are largely 
distributed in the zone and include the M. natalensis known as a potential reservoir 
of LASV. In contrast, the lower prevalence 7%, was found in the middle and lower 
regions of Guinea217. These regions encounter less contact with rodents, perhaps, 
because they are forbidden for consumption amongst certain ethnic groups within the 
region. In Muslim religions, some animals including pork, frog and rodents are re-
garded as unclean, as a result, these animals are excluded from consumption and 
manipulation. On the other hand, LASV contamination is also known to occur through 
contact with contaminated rodents fluids and feces. Therefore, people from other re-
gions might be exposed to LASV infection from rodents that live nearby. However, 
migrated people from the Forested region of Guinea remain the main consumers of 
rodents in other parts of Guinea. Further investigations on LASV seroprevalence in 
other parts of Guinea should consider the origin of people detected with LASV anti-
body. This will bring more understanding about LASV infection occurrence in rodents’ 
consumers, manipulators and close contact.  
Another study carried out in the forested region of Guinea including Gueckedou, Lola 
and Yomou prefectures (n=977) indicated 12.9% and 10% of seropositivity to anti-
LASV IgG respectively in rural and urban areas136. The study used indirect immuno-
fluorescence (IFA) slides from Bernhard Nocht Institute of Hamburg and acetone-
fixed Vero cells infected with LASV antigen of Josiah strain. The main purpose of the 
study was to estimate the prevalence of LASV antibody in human population and 
establish risk factors for LASV infection. In contrast to our study, samples were col-
lected from general population within selected villages regarding people exposure to 
wildlife (e.g. meat consumption) and contact with someone with haemorrhagic symp-
toms. Despite these findings and that of ours, to date Guinea has never officially rec-
orded a LASV outbreak. These serological detected cases might have been mild or 
unrecognized. Alternatively, they might have been attributed to common tropical fe-
brile diseases such as malaria or typhoid fever because of lack of proper diagnostic. 
In the records, one sporadic LASV infection disease case was notified in Mamou in 
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January 29, 2019134. Active contacts tracing and follow up likely indicate no further 
transmission to close relatives and healthcare workers.   
As we only detected IgG antibodies, we suggest that future work should look at a 
number of different targets to confirm prior infections as these results may have oc-
curred from cross reaction to other viruses specifically non-pathogenic arenaviruses. 
It is unfortunate that we could not define the period of exposure as samples were 
collected from healthy individuals with no report of fever symptoms.  Nevertheless, 
this high prevalence rate highlights the severe extent of risk to public health within the 
Macenta zone. It is important to note that our study volunteers entirely claimed having 
reported febrile symptoms several times which might be related either to LASV infec-
tion or other illnesses. It follows that educating illiterate population about reporting 
febrile illnesses could play a key role in early detection of haemorrhagic infection dis-
eases in communities. Although there have been no reported LASV disease out-
breaks at present, measures should be taken to prevent an unpredicted LASV out-
break in the forested region of Guinea. This would include the availability of proper 
haemorrhagic fever diagnostic capabilities in different prefectures of the Forested 
Guinea as that of the European mobile laboratories newly established in Gueckedou 
prefecture (Forested Guinea). Consequently, further studies should strictly investi-
gate LASV strain pathogenicity, population behaviour and immune response to the 
virus in Guinea. This will provide more understanding on the absence of LASV dis-
ease outbreaks in the country regardless its high seroprevalence reported in litera-
ture. In addition, investigating on the virus reservoir, a multimammate mouse, which 
is broadly spread throughout the country will provide clear insight into potential 
Guinea-LASV strain mutations. Finally, based on our findings and that of previous 
studies, we suggest that possibly there is an unrecognized or mild LASV infection 
circulating in the zone. This gives evidence of LASV strain circulation probably with 
less pathogenicity or virulence in Guinea. 
In general, cross-sectional studies encounter various limitations due to their nature. 
As communities are constantly exposed to infections during their lifetime, our study 
cohort involved general population of rural areas including exclusively bushmeat 
hunters and their household family members. However, with regards to the study se-
lection criteria and for ethics reasons; chronic diseases, pregnant women and infants 
under 16 of age would not take part of the survey. Blood samples were then collected 
from 517 volunteers from 44 villages around Macenta prefecture. 
To conclude, our data provides a strong evidence of LASV circulation or related are-
navirus that induces cross reactive NP antibody response in forested region of 
Guinea. The high prevalence rate of 58.41% indicates population exposure to the 
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virus. This could then alert national health authorities (e.g. The Ministry of health) and 
international partners on the necessity of taking further measures to prevent LASV 
infection disease outbreak occurrence in Guinea. Regarding its high prevalence 
which makes it a major concern, more studies to understand LASV and its silent cir-
culation in Guinea are needed. Investigations should include LASV-Guinea strain 
pathogenicity, Guinea population immune response nature to the virus and the virus 
strain mutation in intermediate host.  
 
6.3 Final conclusions and future work.  
Macenta prefecture, the site of our cross-sectional seroprevalence study is in the For-
ested region of the Republic of Guinea (Surface area: 7.046 km2. Population: 278,456 
people. Latitude: 8°32’59.99’’. Longitude: -9°27’59.99’’W). It encounters high biologic 
diversity of fauna and flora which are almost identical through the zone.  
There are different factors that can promote the transmission of zoonotic viruses to 
humans, ranging from geographic distribution of the animal reservoirs or intermediate 
hosts to the mode of exposure and the susceptibility of hosts. In this study, we tried 
to determine the seroprevalence of highly exposed people (e.g. bushmeat hunters 
and their household family members) to EBOV (filovirus) and LASV (arenavirus). 
Though the LASV reservoir is known to be the M. natalensis, the dynamic mode of 
transmission to humans and the pathogenicity of different viral strain is poorly under-
stood in most affected West African countries including Guinea, with no accurate rec-
ord of Lassa fever outbreaks. In contrast, the EBOV reservoir remains unknown de-
spite few discoveries of the viral RNA in some fruit bats12,55,218,62. Therefore, the zo-
onotic transmission of EBOV continues to be a great challenge for scientific world. 
Thus, the zoonotic transmission is only effective via contact (direct or indirect) be-
tween human and wildlife which are actually frequent in communities. However, the 
increase in human activities (e.g. hunting, butchering, skinning), the demographic in-
crease in population and serious climate change (e.g. deforestation) constitute factors 
that impact zoonoses as they promote direct contact between human and animals. 
Our data is the first to investigate the possibility of EBOV circulation in the Macenta 
prefecture prior to the past 2013-2016 EVD outbreak in the country. It also brings 
more evidence about LASV circulation in the Forested region of Guinea as reported 
in previous studies132,136,217,137. The study population comprises the rural and urban 
areas of Macenta prefecture. It is mainly composed of farmers which are involved in 
wildlife animals manipulation through hunting, butchering and consumption. It follows 
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that our findings contribute to understand human behaviour in wild pathogens trans-
mission and disease spill over in communities. It is easily perceived that some of the 
non-significant sociodemographic prevalence differences observed in our study par-
ticipants groups might be real, but the potential limit of sample size collected per 
group might had dramatically reduced the power needed for detection. Therefore, oral 
swab sampling for antibody detection could be a first line of sero-prevalence studies. 
This is due to the fact that more people can be sampled giving enough possibility to 
investigate a large number of samples. Joseph WS Timothy et al. collected oral swab 
from 27 households out of 30 in Meliandou village the index site of the 2013-2016 
outbreak219. 
Our data shows evidence of EBOV antibody detection; however, only a small propor-
tion of EBOV antibody prevalence was found in the zone. Moreover, as the study was 
performed during a non-active EVD outbreak period, we established the prevalence 
of EBOV IgG antibody of past human exposure to EBOV whether from the 2013-2016 
EVD outbreak in West Africa or related to a pre-existing unreported exposure. Further 
investigations to understand EBOV dynamic transmission to human and virus reser-
voir discovery should be conducted in the forested region of Guinea.  
Despite the absence of reported LASV infections outbreak in forested Guinea, our 
data and that of others previously published132,205 indicate the possible circulation of 
LASV in Macenta zone over a long period of time. Comparing our findings to that of 
Lamine et al in 2008; it is consistent that LASV have been actively circulating over 
the entire 9-year time frame (2008 to 2017). This suggests that many LASV infections 
are mild or unreported because of the lack of diagnostic availability in the zone. In 
addition, it indicates that the virus is endemic and has been maintained in the zone 
over years. The presence of LASV IgG antibody indicate the possible existence of 
unrecognised LASV infection or subclinical exposure in the population. Similar ap-
proach to detect haemorrhagic fever antibodies was performed by Jean-Paul Gonza-
lez in 6 central African countries220. In this study, samples were collected from both 
human and animals (wild and domestic) and tested for six (6) antigens amongst which 
LASV and EBOV were included. The study conducted antibodies detection via indi-
rect immunofluorescence assay using Vero E6 cells.  Report indicated 0.2% and 4.5% 
antibody detection respectively for LASV and EBOV. In contrast, we used EBOV an-
tigen and recombinant LASV nucleoprotein to detect respectively anti-EBOV GP 
(12.96%) and anti-LASV IgG (58.41%) antibodies via ELISA test. Further, we found 
2.51% of seropositivity to EBOV via Western blot analysis. 
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With regards to public health concerns, Macenta prefecture as well as other prefec-
tures of the Forested region of Guinea need proper investment to improve haemor-
rhagic fever infection disease surveillance. So, developing EBOV and LASV diagnos-
tic facilities will provide efficient methods of surveillance to evaluate pathogen pres-
ence, spread and risk of contamination in communities. Although, limiting people’s 
contact with virus reservoirs (wildlife) will contribute to the eradication or reduction of 
zoonotic infections. In remote places or rural areas where population rely on bush-
meat for food and trade business, there is high frequency of exposure to multiple viral 
species. To prevent future zoonotic disease outbreaks such as EBOV and LASV, 
effective public health interventions and campaigns that minimizes the risk of infected 
animal contact need to be diffused and directed to both age and sex groups. Although, 
further investigations are needed to better understand human complex relationships 
and exposure to wildlife animals. 
This study, supported by the United State Food and Drug Administration program and 
the University of Kent, uses sero-prevalence to look at the footprint of human infection 
by EBOV and LASV viruses in the Forested region of Guinea in Macenta prefecture. 
The study looked upon the population of rural areas which appears to be highly ex-
posed to multiple viral infections through constant contact with wildlife either by hunt-
ing, trapping or butchering. We performed antibody detection via ELISA, Western blot 
test and Multiplex beads array assay (Flow cytometry). A number of seropositive in-
dividuals were detected for LASV whereas only few EBOV antibody positive persons 
were observed. In accordance with these findings, (i) we suggest that EBOV has been 
circulating in the forested region of Guinea prior to 2013-16 outbreak; (ii) that LASV 
is being circulating in Macenta prefecture as previously described in studies with no 
record of outbreak. 
Finally, this study has provided further insight regarding mild or unrecognized viral 
infections in communities. It has helped to identify practises that promote the trans-
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Appendix 1: Consent form 
(European Mobile Laboratory consortium, EMLab) 
Seroprevalence of emerging disease in Forested 
Guinea, Macenta zone 
 
INVESTIGATORS AND INSTITUTIONS 
 
Professor Miles W. CARROLL, Public Health England, Porton Down-UK. 
Professor Mandy Kader Konde, FOSAD – CEFORPAG, Conakry, Guinea. 
Professor Stephan Gunther, Bernhard Notch Institute of tropical medi-
cine, Hamburg- Germany. 
Mr Joseph Akoi BORE, Ministry of health Guinea. 
 
What is the purpose of this sero-prevalence research in Guinea? 
Emerging diseases are often viral hemorrhagic fevers infections that usually 
occur as epidemics. The past epidemic (2014-2016) of Ebola virus disease 
mainly affected three countries, Guinea, Liberia and Sierra Leone, with more 
than 28,600 reported cases and 11,300 deaths with social and economic im-
pacts. The disease spread beyond these areas with few cases reported in 
other countries of West Africa, Europe and America. 
The aim of this research is to identify, understand and prevent the emergence 
or re-emergence of these hemorrhagic fever diseases as Ebola and Lassa 
virus diseases. The results of this research may be applicable in the future, in 
case of re-emergency of the virus and will be extremely beneficial. 
The only way to document this study is to analyze the blood to see if you have 
had any contact with viruses. We will thus take (10 to 12 ml) on people living 
in areas (villages) where the Ebola disease has had effects and also in the 
zones (villages) where no case of Ebola was declared. These unaffected ar-
eas will be considered as a control. By doing this, we will have a better under-
standing of the sero prevalence induced by Ebola and Lassa infection. The 
samples will be processed at the EMLab Laboratory in Gueckedou and sent 
to research institutions such as Public Health England (PHE-UK) and Bern-





What is the European Mobile Laboratory (EMLab) mission?  
EMLab is a member of the consortium "H2020 Evident" which also includes 
Doctor without border (MSF). EMLab in partnership with the World Health Or-
ganization (WHO) actively participated in the GOARN mission of the WHO in 
Guinea in order to control the Ebola virus epidemic. Since March 2014, EMLab 
was among the first field workers deployed in Guinea as requested by Guinea 
Government. At the end of the epidemic, EMLab performed more than half of 
all Ebola virus disease diagnosis in Guinea. The implementation of this viro-
logic platform diagnosis has greatly helped to eradicate the impact of disease 
on local populations.  
 
What is the aim of these researches?  
Unlike a usual therapeutic approach, the goal of this research is to identify the 
best ways to prevent an emergence or reemergence of hemorrhagic fever 
diseases like Ebola, and then determine the immune response duration in 
peoples cured of Ebola. The results of this research will be applied in the future 
in case of re-emergence of the virus and will be beneficial for everyone. Ebola 
and Lassa diseases are viral hemorrhagic fevers that occur in the form of 
epidemics. The current outbreak (2014) Ebola mainly affected three countries, 
Guinea, Liberia and Sierra Leone, with more than 28,600 reported deaths. The 
disease has spread beyond these areas with reported cases in other west 
African countries, Europe and America.  
We want to have access to low amount of blood samples (12ml) of people 
living in areas (villages) where the Ebola disease has had effects and also in 
areas (villages) where no Ebola case was declared. These non-affected areas 
will be considered as negative. By doing this, we will have a better 
understanding of the sero prevalence induced by infection with Ebola and 
Lassa eventually. The samples will be processed first at the Laboratory in 
Gueckedou and sent to research institutions such as Public Health England 
(PHE-UK) and Bernhard Notch Institute (BNI-Hamburg) approved by the 
European Union consortium for further analysis. 
What did that mean to me? 
If you accept to participate in this study: 
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Health monitoring: a doctor will regularly check your general health 
during study time and offer medical examinations for you if necessary. 
Each person will be individually and secretly informed about his results 
after analyzes. 
 
What are the risks for me and my health? 
Our priority is your wellbeing. Sampling shall be conducted by an expe-
rienced biologist with sterile equipment while following pre-established 
safety procedures by the care center. 
 
What are my benefits of participating in this study? 
Your participation will help to develop effective control measures against Filo-
viruses such as Ebola and Lassa virus diseases that will benefit your family, 
friends and future generations. If you are diagnosed with any disease, we will 
direct you to the appropriate treatment center recommended by your govern-
ment.  
You will receive support as a sign of our gratitude for your time and all ex-
penses related to your participation in this study (travel and food). 
 
If you refuse to participate to this study? 
Your participation is on a voluntary basis and contributes to your well-being. 
You are free to decide whether to take part or not. That will not affect your 
health or personal or professional situation in the future. 
 
What will happen with your blood samples? 
Blood samples will carry a code (identification number of the study) and will 
therefore remain anonymous (no names or other personal information). The 
sample-patient relationship will only be done by a few people directly in-
volved in the study which will respect your anonymity and your privacy. Sam-
ples will first be analyzed by the laboratory in Gueckedou, Guinea, and then 
they will be transported to Europe for further analysis.  
 
Who will have access to the information related to this research? 
All research data is stored on secure computers in rooms dedicated for this 
purpose and protected with passwords. Only a few people directly involved in 
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this research will be allowed to have access to information of the participants 
and in order to verify and ensure that the study is proceeding according to 
defined international standards and that the confidentiality and anonymity of 
participants is preserved. We will only share information and data summarized 
in code, and in constant collaboration with WHO. The identity of the partici-
pants will never be revealed. 
 
Who allowed this research to take place? 
These studies were approved by a committee of local experts in Guinea. 
This committee has ensured that these studies will be conducted according 
to very well-defined standards and safety, welfare and rights of participants 
are always respected. The committee reviewed the research carefully, con-
firmed that they were important for the Guinean population and they followed 
national and international guidelines. 
 
Other questions? 
You can ask any other question to our team involved in this study, and at any 
time. You can also contact the people responsible for the implementation of 
these studies. 
 
 I, ____Volunteers___, certify having a detailed explanation of the subject of 
this study. I understood perfectly what I've read, everything was explained to 
me and I had a complete response and understood all my questions answers. 
I understand that I may change my mind at any time of the study. 
        Thanks to tick. I agree to participate in this study.   
        Thanks to tick. I agree to give 10 to 20 ml of my blood. 
        Thanks to tick. I agree that my samples be stored.   













Appendix 2: Sample collection questioning 
 
Questionnaire 
First and last name: 
Gendre / Sexe 
1- Male : ……          2- Female: ……           3- Poids : ……     
 
4- Age : …….   
Marital statues 
1- Are you married? (if yes) 
2- how many children: ……………… 
 
Volunteers localisation 
1- Préfecture : ………………………………… 
2- Sous-Préfecture : …………………………… 
3- Village : ……………………………….. 
Affected village…..  Unaffected village…… (if yes) 
 
1- How many people survived: ………………… 
 







Hunter (if yes, how do you hunt them?) 
 
1- I use gun: …………………… 
 
2- I use trap: …………………… 
 
3- Other: …………… 
 




Did anyone in your family practice any kind of hunting activity? (if 
yes) 
 
1- What is your relationship to that person? …… 
 
Brush meat consumption (if yes, how did you get them?) 
 
1- From my relative: …………. Specify: ………… 
 
2- I buy it: …………………   Specify: ………… 
 
Clinical history                                 
- Have you ever been diagnosed with any chronicle disease or 
sickness?  
If yes, what was it about? 
…………………………………… 




1- As you were told, did you agree to be part of the research by 
giving your blood?  
 
2- Did you willingly sign the consent form? 
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